Immune modulators for treatment of dent disease type i
By administering a CLCN5-encoding vector and rapamycin to the kidney, Dent disease is treated at its genetic source, improving kidney function and reducing disease symptoms.
Patent Information
- Application Number
- PCT/US2026/028401
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-05-15
- Publication Date
- 2026-11-19
AI Technical Summary
Current treatments for Dent disease, particularly Type I, do not address the genetic root cause and require invasive procedures like kidney transplant and lifelong immune suppression.
Administration of a therapeutic vector encoding a CLCN5 protein, such as a lentiviral or AAV vector, combined with an immune modulator like rapamycin, delivered locally to the kidney to correct the genetic mutation causing Dent disease.
This approach effectively restores normal kidney function by correcting the CLCN5 gene mutation, reducing proteinuria and hypercalciuria, and potentially avoiding severe complications like kidney failure.
Smart Images

Figure IMGF000040_0001 
Figure IMGF000058_0001 
Figure IMGF000072_0001
Abstract
Description
[0001] Atorney Docket Number: 205286-7011W01(00115)
[0002] TITLE OF THE INVENTION
[0003] Immune Modulators for Treatment of Dent Disease Type I
[0004] CROSS REFERENCE TO RELATED APPLICATION
[0005] The present application claims priority under 35 U.S.C. § 119(e) to U.S.
[0006] Provisional Patent Application No. 63 / 807,062, filed May 16, 2025, which is hereby incorporated by reference in its entirety herein.
[0007] SEQUENCE LISTING
[0008] The XML file named “205286_7011 WOl SequenceListing.xml” created on May 1 , 2026, comprising 33,215 bytes, is hereby incorporated by reference in its entirety.
[0009] BACKGROUND OF THE INVENTION
[0010] Dent disease is a chronic kidney disorder characterized by abnormally high amounts of protein and excess calcium in the urine. Dent disease is caused by genetic mutations that reduce the ability of cells of the proximal renal tubule to reabsorb amino acids, small proteins, cations, water, and other substances that have been filtered from the bloodstream. Clinical symptoms of Dent disease appear in childhood and worsen over time. The kidney dysfunction causing Dent disease progressively damages kidney cells and eventually causes a range of symptoms from calcifications in the kidney tissue, kidney stones, abdominal pain, repeated urinary tract infections, chronic kidney disease, and kidney failure.
[0011] Genetically, Dent disease is caused by loss-of-function mutations in either the CLCN5 or OCRL1 genes, which separate the disease into two ty pes. Type I Dent disease is characterized by mutations in the CLCN5 gene, while type 2 Dent disease is associated with mutations OCRL1. Both genes are X-linked and recessive, resulting in the majority of patients being male, though females can be asymptomatic ‘‘carriers’' and can suffer mild hypercalciuria due to random X-chromosome inactivation. Type I Dent disease is more common with around 60% of total cases with Type 2 being 15% of cases and the remaining 25% being of unknown etiology. Type 2 Dent disease is often associated with mild intellectual disability, hypotonia, and mild cataract. Currently there are onlyAtorney Docket Number: 205286-7011W01(00115)
[0012] supportive treatments for Dent disease and none of them target the root of the disease. Severe cases are often treated by kidney transplant, though such a strategy requires identifying a compatible donor, invasive surgery, and life-long immune suppression to delay rejection.
[0013] Thus, there is a need for treatments that correct the mutated genes responsible for Dent disease in order to restore normal kidney function. The current invention addresses these needs.
[0014] SUMMARY OF THE INVENTION
[0015] In one aspect, the present invention provides a method for treating Dent disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a therapeutic vector comprising a nucleic acid encoding a CLCN5 protein and an effective amount of an immune modulator, thereby treating the disease.
[0016] In some embodiments, the therapeutic vector is a lentiviral vector.
[0017] In some embodiments, the therapeutic vector is an adeno-associated virus (AAV) vector.
[0018] In some embodiments, the AAV vector comprises a capsid protein of a serotype selected from the group consisting of AAV1, AAV2, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV 12, AAV-B1, AAV-DJ, AAV-Retro, AAVrh8, AAVrhlO, AAVrh25, Anc80L65, LK03, AAVrhl8, AAVrh74, AAVrh32.33, AAVrh39, AAVrh43, OligoOOl, PHP-B, PHP.eB, and SparklOO.
[0019] In some embodiments, the nucleic acid encoding a CLCN5 protein is operably linked to a promoter that drives the expression of the CLCN5 protein.
[0020] In some embodiments, the promoter is a constitutive promoter.
[0021] In some embodiment, the promoter is an EF-1 a promoter.
[0022] In some embodiments, the therapeutic vector is a lentiviral vector and comprises the nucleic acid sequence set forth in SEQ ID NO. 1.
[0023] In some embodiments, the administration of the therapeutic vector and the immune modulator is delivered locally to the kidney.
[0024] In some embodiments, the local kidney administration is delivered by a route selected from the group consisting of retrograde ureteral injection and ureteroscopy.
[0025] In some embodiments, the immune modulator is rapamycin.Atorney Docket Number: 205286-7011W01(00115)
[0026] In some embodiments, the immune modulator is comprised within a lipid nanoparticle (LNP).
[0027] In some embodiments, the immune modulator is comprised within polymer nanoparticles.
[0028] In some embodiments, the polymer nanoparticle is ImmTOR™.
[0029] In some embodiments, the therapeutic vector and immune modulator are delivered concurrently.
[0030] In another aspect, the current invention provides a method for treating Dent disease in a neonate or pediatric subject in need thereof, the method comprising administering to the subject an effective amount of a lentiviral therapeutic vector comprising a nucleic acid encoding a CLCN5 protein and an effective amount of an immune modulator, thereby treating the disease.
[0031] In some embodiments, the nucleic acid encoding a CLCN5 protein is operably linked to a promoter that drives the expression of the CLCN5 protein.
[0032] In some embodiments, the promoter is a constitutive promoter.
[0033] In some embodiments, the promoter is an EF-la promoter.
[0034] In some embodiments, the lentiviral vector comprises the nucleic acid sequence set forth in SEQ ID NO. 1.
[0035] In some embodiments, the administration of the lentiviral vector and the immune modulator is delivered locally to the kidney.
[0036] In some embodiments, the local kidney administration is delivered by a route selected from the group consisting of retrograde ureteral injection and ureteroscopy.
[0037] In some embodiments, the immune modulator is rapamycin.
[0038] In some embodiments, the immune modulator is comprised within a lipid nanoparticle (LNP).
[0039] In some embodiments, the immune modulator is comprised within polymer nanoparticles.
[0040] In some embodiments, the polymer nanoparticle is ImmTOR™
[0041] In some embodiments, the therapeutic vector and immune modulator are delivered concurrently.
[0042] In another aspect, the current invention provides a method for treating Dent disease in an adult subject in need thereof, the method comprising administering to theAtorney Docket Number: 205286-7011W01(00115)
[0043] subject an effective amount of a therapeutic AAV vector comprising a nucleic acid encoding a CLCN5 protein and an effective amount of an immune modulator, thereby treating the disease.
[0044] In some embodiments, the nucleic acid encoding a CLCN5 protein is operably linked to a promoter that drives the expression of the CLCN5 protein.
[0045] In some embodiments, the promoter is a constitutive promoter.
[0046] In some embodiments, the promoter is an EF-la promoter.
[0047] In some embodiments, the therapeutic vector is a lentiviral vector and comprises the nucleic acid sequence set forth in SEQ ID NO. 1.
[0048] In some embodiments, the administration of the therapeutic vector and the immune modulator is delivered locally to the kidney.
[0049] In some embodiments, the local kidney administration is delivered by a route selected from the group consisting of retrograde ureteral injection and ureteroscopy.
[0050] In some embodiments, the immune modulator is rapamycin.
[0051] In some embodiments, the immune modulator is comprised within a lipid nanoparticle (LNP).
[0052] In some embodiments, the immune modulator is comprised withinpolymer nanoparticles.
[0053] In some embodiments, the polymer nanoparticle is ImmTOR™.
[0054] In some embodiments, the therapeutic vector and immune modulator are delivered concurrently.
[0055] In another aspect, the current invention provides a pharmaceutical composition comprising:
[0056] a) a therapeutic vector comprising a nucleic acid encoding a CLCN5 protein; b) a lipid nanoparticle comprising an immune modulator; and
[0057] c) a pharmacologically acceptable vehicle.
[0058] In some embodiments, the therapeutic vector is a lentiviral vector.
[0059] In some embodiments, the lentiviral vector comprises an amino acid sequence of SEQ ID NO: 1.
[0060] In some embodiments, the therapeutic vector is an AAV vector.
[0061] In some embodiments, the AAV vector comprises a capsid protein of a serotype selected from the group consisting of AAV1, AAV2, AAV3, AAV3B, AAV4, AAV5,Atorney Docket Number: 205286-7011W01(00115)
[0062] AAV6, AAV7, AAV8, AAV9, AAV 12, AAV-B1, AAV-DJ, AAV-Retro, AAVrh8, AAVrhlO, AAVrh25, Anc80L65, LK03, AAVrhl8, AAVrh74, AAVrh32.33, AAVrh39, AAVrh43, OligoOOl, PHP-B, PHP.eB, and SparklOO.
[0063] In another aspect, the current invention provides a method for correcting a mutation in the CLCN5 gene in a subject in need thereof, comprising administering to the subject with a therapeutic vector comprising a nucleic acid encoding a CLCN5 protein and a lipid nanoparticle (LNP) comprising an immune modulator.
[0064] In some embodiments, the therapeutic vector is a lentiviral vector.
[0065] In some embodiments, the therapeutic vector is a AAV vector.
[0066] In some embodiments, the AAV vector comprises a capsid protein of a serotype selected from the group consisting of AAV1, AAV2, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV12, AAV-B1, AAV-DJ, AAV-Retro, AAVrh8, AAVrhlO, AAVrh25, Anc80L65, LK03, AAVrhl8. AAVrh74, AAVrh32.33, AAVrh39, AAVrh43, OligoOOl, PHP-B, PHP.eB, and SparklOO.
[0067] In some embodiments, the nucleic acid vector is operably linked to a promoter that drives expression of the CLCN5 protein.
[0068] In some embodiments, the promoter is a constitutive promoter.
[0069] In some embodiments, the promoter is an EF-la promoter.
[0070] In some embodiments, the lentiviral vector is encoded by the nucleic acid sequence set forth in SEQ ID NO: 1.
[0071] In some embodiments, the immune modulator is comprised within polymeric microspheres.
[0072] In some embodiments, the polymeric microspheres are formulated for sustained release of the immune modulator.
[0073] BRIEF DESCRIPTION OF THE DRAWINGS
[0074] The following detailed description of specific embodiments of the invention will be better understood when read in conjunction with the appended drawings. For the purpose of illustrating the invention, there are shown in the drawings exemplary embodiments. It should be understood, however, that the invention is not limited to the precise arrangements and instrumentalities of the embodiments shown in the drawings.Atorney Docket Number: 205286-7011W01(00115)
[0075] Figs. 1A-1B are diagrams showing the mutational landscape of the CLCN5 gene in Dent disease. FIG. 1 A is a diagram of the location of the missense mutations over the CLCN5 gene product C1C-5 . FIG. IB is a chart showing the frequency of each ty pe of mutation.
[0076] Figs 2A-2B illustrate that LV but not adeno-associated virus (AAV) based vectors resulted in improved long-term treatment of Dent disease mice when delivered to neonates. Fig. 3A. Western blots (WB) detecting urinary vitamin D binding protein (DBP) 10 months after LV mediated CLCN5 cDNA delivery. Fig. 3B. Western blots detecting urinary DBP at different times after AAV-mediated CLCN5 cDNA delivery. Data representative of 5 mutant mice injected with AAV. For (Fig. 2A & 2B), viral vector injection was performed 1 day after birth. Protein densitometry was analyzed with ImageJ. Equal volumes of urine were loaded for western blot analyses and loading of samples from wild-type and treated mice was confirmed by megalin yvestem blot studies.
[0077] Figs. 3A-3D illustrate that Rapamycin microsphere co delivery with LV CLCN5 produces sustained reductions in urinary P2 microglobulin in mutant mice. (Fig. 3A) Western blot analysis of urinary P2 microglobulin in mutant mice treated yvith LV CLCN5 alone. (Fig. 3B) Densitometric quantification of P2 microglobulin bands shown in panel A. ** indicates p < 0.01 by t test between the indicated groups. (Fig. 3C) Western blot analysis of urinary' P2 microglobulin in mutant mice treated yvith LV CLCN5 in combination yvith rapamycin loaded microspheres. (Fig. 3D) Densitometric quantification of P2 microglobulin bands shown in panel C. * indicates p < 0.05 and ** indicates p < 0.01 by t test betyveen the indicated groups. Coomassie stained SDS PAGE gels demonstrated comparable total urinary protein loading, and band intensities were normalized accordingly.
[0078] Figs. 4A-4D illustrate that rapamycin microsphere co delivery' enhances C1C 5 expression following LV CLCN5 gene delivery. (Fig. 4A) Semiquantitative PCR analysis of lentiviral genomic DNA in kidneys of mice treated with LV CLCN5 yvith or without rapamycin loaded microspheres. Mouse Dmd DNA served as an internal control. (Fig. 4B) Semiquantitative RT PCR analysis of CLCN5 transgene mRNA expressed from the LV vector in kidney tissues. Mouse Ppib mRNA served as an internal control; primers were designed to span introns to avoid amplification of genomic DNA. (Fig. 4C) Western blot analysis of C1C 5 protein expression in kidneys of mutant mice treated with LVAtorney Docket Number: 205286-7011W01(00115)
[0079] CLCN5 in the presence or absence of rapamycin microspheres. (Fig. 4D) Densitometric quantification of C1C 5 bands shown in panel C. ** indicates p < 0.01 by t test between the indicated groups.
[0080] Figs. 5A-5I illustrate the transient therapeutic effects following AAV9 CLCN5 delivery to neonatal mutant mice. (Fig. 5A) Western blot analysis of urinary vitamin D-binding protein (VDBP) and P2 microglobulin in one month old mutant mice with or without AAV9 CLCN5 treatment. (Fig. 5B) Densitometric quantification of protein bands shown in panel A. (Fig. 5C) ELISA measurements of urinary P2 microglobulin and vitamin D-binding protein at indicated time points following AAV9 CLCN5 treatment. (Fig. 5D) Western blot analysis of urinary vitamin D-binding protein at indicated times after AAV9 CLCN5 delivery. (Fig. 5E) Densitometric quantification of bands shown in panel D. (Fig. 5F) Western blot analysis of urinary vitamin D-binding protein and P2 microglobulin 1 and 4 months after AAV9 CLCN5 treatment. (Fig. 5G) Densitometric quantification of bands shown in panel F. (Fig. 5H) ELISA analysis of urinary albumin at indicated times following AAV9 CLCN5 treatment. (Fig. 51) Analysis of urinary calcium excretion at indicated times following AAV9 CLCN5 treatment.
[0081] Figs. 6A-6D illustrate the persistent transgene expression following AAV hCLCN5 delivery to neonatal mutant mice despite loss of therapeutic effects. (Fig. 6A) PCR detection of AAV vector DNA in kidney genomic DNA from AAV9 hCLCN5-treated mutant mice. Genomic DNA from a lentiviral vector-treated mouse served as a positive control, and mouse Dmd DNA was used as an internal X chromosome control. (Fig. 6B) RT PCR detection of hCLCN5 cDNA in kidney tissues. Mouse Ppib was used as an internal mRNA control. Detection was dependent on the presence of reverse transcriptase, excluding amplification from contaminating vector DNA. (Fig. 6C) Western blot analysis of C1C 5 expression in kidneys of mutant mice four months after AAV9 hCLCN5 treatment. Numbers below each lane indicate band intensities normalized to the corresponding P actin signal. (Fig. 6D) Immunofluorescence staining of C1C 5 in kidney sections from treated mutant mice, showing characteristic localization at the tubular lumen. C1C 5 signals are show n in red, and nuclei are show n in blue. All mice were euthanized at four months of age.
[0082] Fig. 7 illustrates AAV mediated expression of C1C 5 in kidney tubule segments.Atorney Docket Number: 205286-7011W01(00115)
[0083] Representative immunofluorescence images of kidney sections from AAV9 CLCN5-treated mutant mice. Nuclei are stained with DAPI (blue), C1C 5 signals are shown in red, and tubular segment-specific markers are shown in green. Lotus tetragonolobus lectin (LTL) labels proximal tubules, peanut agglutinin (PNA) labels distal tubules / medullary thick ascending limb, and aquaporin 2 (AQP2) labels collecting ducts. Co localization of C1C 5 with tubular markers appears yellow.
[0084] Figs. 8A-8D illustrate that AAV9 CLCN5 delivery to adult kidneys does not reduce urinary protein markers. (Fig. 8A) Western blot analysis of urinary' P2 microglobulin and vitamin D-binding protein 1 month after AAV9 CLCN5 delivery. (Fig. 8B) Western blot analysis of urinary 2 microglobulin and vitamin D-binding protein 4 months after AAV9 CLCN5 delivery'. (Fig. 8C) Western blot analysis of urinary P2 microglobulin and vitamin D-binding protein 1 month after co delivery of AAV9 CLCN5 and rapamycin loaded microspheres. (Fig. 8D) Western blot analysis of urinary P2 microglobulin and vitamin D-binding protein 4 months after co delivery of AAV9 CLCN5 and rapamycin loaded microspheres.
[0085] Figs. 9A-9F illustrate the assessment of AAV mediated CLCN5 expression in adult kidneys with and without rapamycin co delivery. (Fig. 9A) PCR detection of AAV vector DNA in kidneys of adult mutant mice treated with AAV9 CLCN5 alone. Genomic DNA from a lentiviral vector treated mouse served as a positive control, and mouse Dmd DNA was used as an internal control. Samples #l-#5 represent individual animals. (Fig.
[0086] 9B) PCR detection of AAV vector DNA in kidneys of adult mutant mice treated with AAV9 CLCN5 plus rapamycin loaded microspheres. (Fig. 9C) RT PCR detection of codon optimized human CLCN5 mRNA in kidneys of adult mutant mice treated with AAV9 CLCN5 alone. Mouse Ppib served as an internal control. (Fig. 9D) RT PCR detection of CLCN5 mRNA in kidneys of adult mutant mice treated with AAV9 CLCN5 and rapamycin loaded microspheres. (Fig. 9E) Western blot analysis of C1C 5 protein expression in kidneys of adult mutant mice treated with AAV9 CLCN5 with or without rapamycin microspheres. P actin served as a loading control. Densitometric quantification is shown on the right. (Fig. 9F) Immunofluorescence detection of C1C 5 expression in kidney sections following AAV mediated gene therapy. Nuclei are stained with DAPI (blue), and C1C 5 signals are shown in red. See Fig.6D for immunostaining of kidney sections from wild type and untreated mutant mice.Atorney Docket Number: 205286-7011W01(00115)
[0087] Fig. 10 illustrates the expression of vitamin D binding protein (DBP) in mutant mice at one or three months post-treatment with LV CLCN5 and with or without treatment with rapamycin
[0088] Fig. 11 illustrates the spatial distribution of C1C 5 expression following neonatal AAV9 CLCN5 delivery. Overview of C1C 5 expression in kidneys of AAV9 CLCN5-treated mutant mice at 3 weeks and 4 months post gene delivery, illustrating age dependent redistribution of C1C 5-positive tubules.
[0089] Figs. 12A-12D illustrates that urinary calcium excretion was not significantly different between wild-type and ClC-5-null mice. (Fig. 12A) Urinary calcium, 24-hour calcium, and calcium excretion / g of body weight in wildtype and C1C-5 null mice 24hours after treatment with IM or 10M of rapamycin. (Fig. 12B) Urine volume and urine volume / g of body weight excrete by wildtype or C1C-5 null mice after 24 hours of IM or 10M rapamycin treatment. (Fig. 12C) Urinary protein, total protein, and urinary protein / g body weight from wildtype or C1C-5 null mice after 24 hours treatment with IM or 10M rapamycin. (Fig. 12D) P2- microglobulin (B2M) concentration, total B2M generated, and B2M / g body weight from wildty pe and C1C-5 null mice after 24 hours of treatment with IM or 10M rapamycin.
[0090] Figs. 13A-13B illustrate urinary vitamin D-binding protein and ALB in 10- to 11-month-old wild-type and mutant mice. (Fig. 13A) Urinary vitamin D-binding protein data. (Fig. 13B) Urinary ALB data. Each point represents a distinct urine sample. Data are shown as median with 95% confidence interval. Statistical analysis was performed using the Kruskal-Wallis test followed by Dunn’s multiple comparisons. *. **, *** indicate p < 0.05, 0.01, and 0.001, respectively.
[0091] Figs. 14A-14C illustrate Masson trichrome staining for assessment of kidney fibrosis. (Fig. 14A) Representative Masson trichrome-stained kidney sections from wild-type, null, and E211A mutant mice. For each genotype and age group, 5-7 mice were analyzed. (Fig. 14B) Quantification of fibrosis-positive areas in kidney sections from 5-month-old mice. The left panel compares all three genotypes; the right panel shows pooled data from wild-type and null mice, which do not differ significantly. Each data point represents one mouse and corresponds to the mean percentage of
[0092] collagen-positive area calculated from 4-6 sections per mouse and 2-4 images per section. Total number of images analyzed: wild-type (61), null (71), E211A (73). (Fig.Atorney Docket Number: 205286-7011W01(00115)
[0093] 14C) Quantification of fibrosis-positive areas in kidney sections from 18-month-old mice. Each data point represents one mouse and corresponds to the mean percentage of collagen-positive area calculated from 2-7 sections per mouse and 1-4 images per section. Total number of images analyzed: wild-type (89), null (90), E211A (53). Red lines denote the median with interquartile range. Statistical significance was assessed using the Kruskal-Wallis test followed by Dunn’s multiple-comparison test. * and ** indicate p < 0.05 and p < 0.01, respectively.
[0094] Figs. 15A-15F illustrate the analysis of glomeruli in different mutants. (Fig. 15A) Representative images of glomeruli from trichrome-stained kidney sections of wild-type and mutant mice. For each genotype and age group, 5-7 mice were analyzed. * indicates enlarged Bowman’s space. (Figs. 15B, 15C) Quantification of glomerular tuft size (Fig.
[0095] 15B) and Bowman’s space (Fig. 15C) in kidney sections from 5-month-old mice. Each data point represents one mouse and corresponds to the mean value calculated from 4-6 sections per mouse, 2-4 images per section, and 3-6 glomeruli per image. Total glomeruli analyzed: wild type (110), null (146), E211A (128). (Figs. 15D, 15E) Quantification of glomerular tuft size (Fig. 18D) and Bowman’s space (Fig. 15E) in kidney sections from 18-month-old mice. Each data point represents one mouse and corresponds to the mean value calculated from 2-7 sections per mouse. 1-4 images per section, and 3-6 glomeruli per image. Total glomeruli analyzed: wild type (209), null (157), E211A (151). For (B-E), red lines denote the median with interquartile range. Statistical analysis: Kruskal-Wallis test with Dunn’s multiple comparisons. * and ** indicate p < 0.05 and p <0.01, respectively. (Fig. 15F). Cysts of unknown origin in 18-month E211A mutants (the bottom left shows the kidney capsule).
[0096] Figs. 16A-16C illustrate the reduction of Wilms tumor protein and nephrin expression in kidneys of 18-month-old E211A mutants. (Fig. 16A) Immunofluorescence analysis of Wilms tumor protein and nephrin. Glomeruli on the right side of the images represent superficial glomeruli. The Wilms tumor protein and nephrin signals were shown red and the nuclei were shown blue. (Figs. 1 B, 1 C) Quantification of Wilms tumor protein-positive podocytes within glomerular tufts from 5- and 18-month-old mice. Five mice were analyzed per group, except for 18-month C1C-5 null mice, which included 6 mice. At least 10 glomeruli were analyzed per mouse, except for three 18-month-old mice, for which only 4, 7 and 7 glomeruli, respectively, were analyzed due to the limitedAtorney Docket Number: 205286-7011W01(00115)
[0097] intact glomeruli available. A total of 152, 136 and 134 glomeruli were analyzed for 5-month-old wild type, C1C-5 null, and E211A mutant mice, respectively, whereas 132, 194 and 78 glomeruli were analyzed for the corresponding 18-month-old wild type, C1C-5 null, and E211 A mutant mice. Each data point represents one mouse; red lines indicate the median and interquartile range. Statistical analysis was performed using the Kruskal-Wallis test with Dunn’s multiple comparisons, ns, not significant; ***, p < 0.001.
[0098] Figs. 17A-17B illustrate a depth analysis of superficial glomeruli. (Fig. 17A) Representative trichrome-stained images illustrating the depth of superficial glomeruli (indicated by a line). The kidney capsule is located on the right side of each image.
[0099] (Fig. 17B) Quantification of superficial glomerular depth in 1- and 5-month-old mice. Each point indicates the average superficial glomerular depth of a mouse calculated from at least 25 glomeruli. Red lines denote the median and the interquartile range. Statistical analysis: Kruskal-Wallis test with Dunn’s multiple comparisons. * and ** indicate p < 0.05 and p<0.01 respectively.
[0100] Fig. 18 illustrates an analysis of C1C-5 expression in mice of different genotypes. Representative images of three mice for each genotype are shown. Immunofluorescent analyses used identical staining procedures, image acquisition, and display settings. C1C-5 signals are shown in red; nuclei in blue. The boxed areas on the top images were shown with high magnifications.
[0101] DETAILED DESCRIPTION
[0102] Definitions
[0103] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although any methods and materials similar or equivalent to those described herein can be used in the practice for testing of the present invention, exemplary materials and methods are described herein. In describing and claiming the present invention, the following terminology will be used.
[0104] It is also to be understood that the terminology' used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.Atorney Docket Number: 205286-7011W01(00115)
[0105] The articles “a”, ‘'an’’, and "the" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.
[0106] The term “AAV vector” as used herein refers to a polynucleotide vector comprising one or more genes of interest (or transgenes) and associated promoters and enhancers that are flanked by AAV terminal repeat sequences (ITRs). AAV vectors can be produced and packaged into infectious viral particles when present in a host cell that has been transfected with one or more helper plasmids encoding and expressing rep and cap proteins and one or more proteins from adenovirus open reading frame E4orf6. The AAV vectors may be operably linked to promoter and enhancer sequences that can regulate the expression of the
[0107] protein encoded by the AAV vector.
[0108] The terms “AAV virion” or “AAV viral particle” or “AAV vector particle” as used herein refers to a viral particle composed of capsid proteins from at least one AAV serotype surrounding a polynucleotide AAV vector. If the particle comprises a heterologous polynucleotide (i.e. a polynucleotide other than a wild-type AAV genome such as a transgene to be delivered to a mammalian cell), it is typically referred to as an “AAV vector particle” or simply an “AAV vector”. Thus, production of AAV vector particle necessarily includes production of AAV vector, as such a vector is contained within an AAV vector particle.
[0109] “About” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20% or ±10%, more preferably ±5%, even more preferably ±1%, and still more preferably ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.
[0110] A “biomarker” or “marker” as used herein generally refers to a nucleic acid molecule, clinical indicator, protein, or other analyte that is associated with a disease. In certain embodiments, a nucleic acid biomarker is indicative of the presence in a sample of a pathogenic organism, including but not limited to, viruses, viroids, bacteria, fungi, helminths, and protozoa. In various embodiments, a marker is differentially present in a biological sample obtained from a subject having or at risk of developing a disease (e.g., an infectious disease) relative to a reference. A marker is differentially present if the mean or median level of the biomarker present in the sample is statistically different fromAtorney Docket Number: 205286-7011W01(00115)
[0111] the level present in a reference. A reference level may be, for example, the level present in an environmental sample obtained from a clean or uncontaminated source. A reference level may be, for example, the level present in a sample obtained from a healthy control subject or the level obtained from the subject at an earlier timepoint, i.e., prior to treatment. Common tests for statistical significance include, among others, t-test.
[0112] ANOVA, Kruskal-Wallis, Wilcoxon, Mann-Whitney and odds ratio. Biomarkers, alone or in combination, provide measures of relative likelihood that a subject belongs to a phenotypic status of interest. The differential presence of a marker of the invention in a subject sample can be useful in characterizing the subject as having or at risk of developing a disease (e.g., an infectious disease), for determining the prognosis of the subject, for evaluating therapeutic efficacy, or for selecting a treatment regimen.
[0113] By ‘‘agent” is meant any nucleic acid molecule, small molecule chemical compound, antibody, or polypeptide, or fragments thereof.
[0114] By “alteration” or “change” is meant an increase or decrease. An alteration may be by as little as 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, or by 40%, 50%, 60%, or even by as much as 70%, 75%, 80%, 90%, or 100%.
[0115] By "biologic sample" is meant any tissue, cell, fluid, or other material derived from an organism.
[0116] By "capture reagent" is meant a reagent that specifically binds a nucleic acid molecule or polypeptide to select or isolate the nucleic acid molecule or polypeptide.
[0117] As used herein, the terms “determining”, “assessing”, “assaying”, “measuring” and “detecting” refer to both quantitative and qualitative determinations, and as such, the term “determining” is used interchangeably herein with “assaying,” “measuring,” and the like. Where a quantitative determination is intended, the phrase “determining an amount” of an analyte and the like is used. Where a qualitative and / or quantitative determination is intended, the phrase “determining a level” of an analyte or “detecting” an analyte is used.
[0118] The terms “Dent disease” or “Dent’s disease” as used herein refer to an X-hnked renal syndrome of low molecular weight proteinuria, hypercalciuria, aminoaciduria, and hypophosphatemia caused by mutational defects in the genes encoding CLCN5 and / or OCRL1 proteins resulting in the partial or complete loss of function of these genes. Loss of CLCN5 is associated with Type I Dent disease, while loss of OCRL1 is associated with Type 2 Dent disease.Atorney Docket Number: 205286-7011W01(00115)
[0119] By "detectable moiety" is meant a composition that when linked to a molecule of interest renders the latter detectable, via spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioactive isotopes, magnetic beads, metallic beads, colloidal particles, fluorescent dyes, electron-dense reagents, enzymes (for example, as commonly used in an ELISA), biotin, digoxigenin, or haptens.
[0120] A “disease” is a state of health of an animal wherein the animal cannot maintain homeostasis, and wherein if the disease is not ameliorated then the animal’s health continues to deteriorate. In contrast, a “disorder” in an animal is a state of health in which the animal can maintain homeostasis, but in which the animal’s state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the animal's state of health.
[0121] “Effective amount” or “therapeutically effective amount” are used interchangeably herein, and refer to an amount of a compound, formulation, material, or composition, as described herein effective to achieve a particular biological result or provides a therapeutic or prophylactic benefit. Such results may include, but are not limited to, anti-tumor activity as determined by any means suitable in the art.
[0122] “Encoding” refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom. Thus, a gene encodes a protein if transcription and translation of mRNA corresponding to that gene produces the protein in a cell or other biological system. Both the coding strand, the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and the non-coding strand, used as the template for transcription of a gene or cDNA. can be referred to as encoding the protein or other product of that gene or cDNA.
[0123] As used herein “endogenous” refers to any material from or produced inside an organism, cell, tissue or system.
[0124] The term “epitope” as used herein is defined as a small chemical molecule on an antigen that can elicit an immune response, inducing B and / or T cell responses. An antigen can have one or more epitopes. Most antigens have many epitopes; i.e., they areAtorney Docket Number: 205286-7011W01(00115)
[0125] multivalent. In general, an epitope is roughly about 10 amino acids and / or sugars in size. Preferably, the epitope is about 4-18 amino acids, more preferably about 5-16 amino acids, and even more most preferably 6-14 amino acids, more preferably about 7-12, and most preferably about 8-10 amino acids. One skilled in the art understands that generally the overall three-dimensional structure, rather than the specific linear sequence of the molecule, is the main criterion of antigenic specificity and therefore distinguishes one epitope from another. Based on the present disclosure, a peptide used in the present invention can be an epitope.
[0126] As used herein, the term "exogenous’' refers to any material introduced from or produced outside an organism, cell, tissue or system.
[0127] The term “expression” as used herein is defined as the transcription and / or translation of a particular nucleotide sequence driven by its promoter.
[0128] “Expression vector” refers to a vector comprising a recombinant polynucleotide comprising expression control sequences operatively linked to a nucleotide sequence to be expressed. An expression vector comprises sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or in an in vitro expression system. Expression vectors include all those known in the art, such as cosmids, plasmids (e.g., naked or contained in liposomes) and viruses (e.g., Sendai viruses, lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) that incorporate the recombinant polynucleotide.
[0129] “Encoding” refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA. or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (z.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom. Thus, a gene encodes a protein if transcription and translation of mRNA corresponding to that gene produces the protein in a cell or other biological system. Both the coding strand, the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and the non-coding strand, used as the template for transcription of a gene or cDNA, can be referred to as encoding the protein or other product of that gene or cDNA.
[0130] By "fragment" is meant a portion of a nucleic acid molecule. This portion contains, preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of theAtorney Docket Number: 205286-7011W01(00115)
[0131] entire length of the reference nucleic acid molecule or polypeptide. A fragment may contain 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 nucleotides.
[0132] “Homologous” as used herein, refers to the subunit sequence identity between two polymeric molecules, e.g, between two nucleic acid molecules, such as, two DNA molecules or two RNA molecules, or between two polypeptide molecules. When a subunit position in both of the two molecules is occupied by the same monomeric subunit; e.g., if a position in each of two DNA molecules is occupied by adenine, then they are homologous at that position. The homology between two sequences is a direct function of the number of matching or homologous positions; e.g., if half (e.g, five positions in a polymer ten subunits in length) of the positions in two sequences are homologous, the two sequences are 50% homologous; if 90% of the positions (e.g., 9 of 10), are matched or homologous, the two sequences are 90% homologous.
[0133] "Hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleobases. For example, adenine and thymine are complementary nucleotides that pair through the formation of hydrogen bonds.
[0134] “Identity” as used herein refers to the subunit sequence identity between two polymeric molecules particularly between two amino acid molecules, such as, between two polypeptide molecules. When two amino acid sequences have the same residues at the same positions; e.g., if a position in each of two polypeptide molecules is occupied by an Arginine, then they are identical at that position. The identity or extent to which two amino acid sequences have the same residues at the same positions in an alignment is often expressed as a percentage. The identity between two amino acid sequences is a direct function of the number of matching or identical positions; e.g., if half (e.g., five positions in a polymer ten amino acids in length) of the positions in two sequences are identical, the two sequences are 50% identical; if 90% of the positions (e.g., 9 of 10). are matched or identical, the two amino acids sequences are 90% identical.
[0135] The term “immune response” as used herein is defined as a cellular response to an antigen that occurs when lymphocytes identify antigenic molecules as foreign and induce the formation of antibodies and / or activate lymphocytes to remove the antigen.
[0136] The term “immunosuppressive” is used herein to refer to reducing overall immune response.Atorney Docket Number: 205286-7011W01(00115)
[0137] As used herein, an "instructional material” includes a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of the compositions and methods of the invention. The instructional material of the kit of the invention may, for example, be affixed to a container which contains the nucleic acid, peptide, and / or composition of the invention or be shipped together with a container which contains the nucleic acid, peptide, and / or composition. Alternatively, the instructional material may be shipped separately from the container with the intention that the instructional material and the compound be used cooperatively by the recipient.
[0138] The terms "isolated," "purified," or "biologically pure" refer to material that is free to varying degrees from components which normally accompany it as found in its native state. "Isolate" denotes a degree of separation from original source or surroundings.
[0139] "Purify" denotes a degree of separation that is higher than isolation. A "purified" or "biologically pure" protein is sufficiently free of other materials such that any impurities do not materially affect the biological properties of the protein or cause other adverse consequences. That is, a nucleic acid or peptide of this invention is purified if it is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. Purity and homogeneity are typically determined using analytical chemistry techniques, for example, polyacrylamide gel electrophoresis or high-performance liquid chromatography. The term "purified" can denote that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. For a protein that can be subjected to modifications, for example, phosphorylation or glycosylation, different modifications may give rise to different isolated proteins, which can be separately purified.
[0140] A “lenti virus” as used herein refers to a genus of the Retroviridae family.
[0141] Lentiviruses are unique among the retroviruses in being able to infect non-dividing cells; they can deliver a significant amount of genetic information into the DNA of the host cell, so they are one of the most efficient methods of a gene delivery vector. HIV, SIV, and FIV are all examples of lentiviruses. Vectors derived from lentiviruses offer the means to achieve significant levels of gene transfer in vivo.
[0142] By "marker profile" is meant a characterization of the signal, level, expression or expression level of two or more markers (e.g., polynucleotides).Atorney Docket Number: 205286-7011W01(00115)
[0143] By the term “microbe” is meant any and all organisms classed within the commonly used term “microbiology,” including but not limited to, bacteria, viruses, fungi and parasites.
[0144] By the term “microarray” is meant a collection of nucleic acid probes immobilized on a substrate. As used herein, the term "nucleic acid" refers to deoxyribonucleotides, ribonucleotides, or modified nucleotides, and polymers thereof in single- or doublestranded form. The term encompasses nucleic acids containing know n nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non- naturally occurring. Nucleic acid molecules useful in the methods of the invention include any nucleic acid molecule that specifically binds a target nucleic acid (e.g., a nucleic acid biomarker). Such nucleic acid molecules need not be 100% identical with an endogenous nucleic acid sequence but will typically exhibit substantial identity.
[0145] Polynucleotides having "substantial identity" to an endogenous sequence are typically capable of hybridizing with at least one strand of a double-stranded nucleic acid molecule. By "hybridize" is meant pair to form a double-stranded molecule between complementary polynucleotide sequences (e.g., a gene described herein), or portions thereof, under various conditions of stringency. (See, e.g.. Wahl, G. M. and S. L. Berger (1987) Methods EnzymoL 152:399; Kimmel, A. R. (1987) Methods Enzymol. 152:507).
[0146] By the term “modulating,” as used herein, is meant mediating a detectable increase or decrease in the level of a response in a subject compared with the level of a response in the subject in the absence of a treatment or compound, and / or compared with the level of a response in an otherwise identical but untreated subject. The term encompasses perturbing and / or affecting a native signal or response thereby mediating a beneficial therapeutic response in a subject, preferably, a human.
[0147] In the context of the present invention, the following abbreviations for the commonly occurring nucleic acid bases are used. “A” refers to adenosine, “C” refers to cytosine. “G” refers to guanosine, “T” refers to thymidine, and “U” refers to uridine.
[0148] “Parenteral” administration of an immunogenic composition includes, e.g., subcutaneous (s.c.), intravenous (i.v.), intramuscular (i.m.), or intrastemal injection, or infusion techniques.
[0149] As used herein, the terms “peptide,” “polypeptide.” and “protein” are used interchangeably, and refer to a compound comprised of amino acid residues covalentlyAtorney Docket Number: 205286-7011W01(00115)
[0150] linked by peptide bonds. A protein or peptide must contain at least two amino acids, and no limitation is placed on the maximum number of amino acids that can comprise a proteins or peptide’s sequence. Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds. As used herein, the term refers to both short chains, which also commonly are referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types. “Polypeptides” include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, among others. The polypeptides include natural peptides, recombinant peptides, synthetic peptides, or a combination thereof.
[0151] By "reference" is meant a standard of comparison. As is apparent to one skilled in the art, an appropriate reference is where an element is changed in order to determine the effect of the element. In one embodiment, the level of a target nucleic acid molecule present in a sample may be compared to the level of the target nucleic acid molecule present in a clean or uncontaminated sample. For example, the level of a target nucleic acid molecule present in a sample may be compared to the level of the target nucleic acid molecule present in a corresponding healthy cell or tissue or in a diseased cell or tissue (e.g., a cell or tissue derived from a subject having a disease, disorder, or condition).
[0152] As used herein, the term “sample” includes a biologic sample such as any tissue, cell, fluid, or other material derived from an organism.
[0153] By “specifically binds” is meant a compound (e.g., nucleic acid probe or primer) that recognizes and binds a molecule (e g., a nucleic acid biomarker), but which does not substantially recognize and bind other molecules in a sample, for example, a biological sample.
[0154] By "substantially identical" is meant a polypeptide or nucleic acid molecule exhibiting at least 50% identity to a reference amino acid sequence (for example, any one of the amino acid sequences described herein) or nucleic acid sequence (for example, any one of the nucleic acid sequences described herein). Preferably, such a sequence is at least 60%, more preferably 80% or 85%, and more preferably 90%, 95%, 96%, 97%, 98%, orAtorney Docket Number: 205286-7011W01(00115)
[0155] even 99% or more identical at the amino acid level or nucleic acid to the sequence used for comparison.
[0156] Sequence identity is ty pically measured using sequence analysis software (for example, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center. 1710 University Avenue, Madison, Wis.
[0157] 53705, BUAST, BESTFIT, GAP, or PILEUP / PRETTYBOX programs). Such software matches identical or similar sequences by assigning degrees of homology' to various substitutions, deletions, and / or other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. In an exemplary approach to determining the degree of identity, a BLAST program may be used, with a probability score between e’3and e-100indicating a closely related sequence.
[0158] By the term “substantially microbial hybridization signature” is a relative term and means a hybridization signature that indicates the presence of more microbes in a tumor sample than in a reference sample. By the term “substantially not a microbial hybridization signature” is a relative term and means a hybridization signature that indicates the presence of less microbes in a reference sample than in a tumor sample.
[0159] By "subject" is meant a mammal, including, but not limited to, a human or nonhuman mammal, such as a bovine, equine, canine, ovine, feline, mouse, or monkey. The term “subject” may refer to an animal, which is the object of treatment, observation, or experiment (e.g., a patient).
[0160] By "target nucleic acid molecule" is meant a polynucleotide to be analyzed. Such polynucleotide may be a sense or antisense strand of the target sequence. The term "target nucleic acid molecule" also refers to amplicons of the original target sequence. In various embodiments, the target nucleic acid molecule is one or more nucleic acid biomarkers.
[0161] A “target site” or “target sequence” refers to a genomic nucleic acid sequence that defines a portion of a nucleic acid to which a binding molecule may specifically bind under conditions sufficient for binding to occur.
[0162] The term “transfected” or “transformed” or “transduced” as used herein refers to a process by which exogenous nucleic acid is transferred or introduced into the host cell. A “transfected” or “transformed” or “transduced” cell is one which has been transfected,Atorney Docket Number: 205286-7011W01(00115)
[0163] transformed or transduced with exogenous nucleic acid. The cell includes the primary subject cell and its progeny.
[0164] The term “therapeutic” as used herein means a treatment and / or prophylaxis. A therapeutic effect is obtained by suppression, remission, or eradication of a disease state.
[0165] As used herein, the terms "treat," treating," "treatment," and the like refer to reducing or ameliorating a disorder and / or symptoms associated therewith. It will be appreciated that, although not precluded, treating a disorder or condition does not require that the disorder, condition or symptoms associated therewith be completely eliminated.
[0166] A “vector” is a composition of matter which comprises an isolated nucleic acid and which can be used to deliver the isolated nucleic acid to the interior of a cell.
[0167] Numerous vectors are known in the art including, but not limited to, linear polynucleotides, polynucleotides associated with ionic or amphiphilic compounds, plasmids, and viruses. Thus, the term “vector” includes an autonomously replicating plasmid or a virus. The term should also be construed to include non-plasmid and non-viral compounds which facilitate transfer of nucleic acid into cells, such as, for example, polylysine compounds, liposomes, and the like. Examples of viral vectors include, but are not limited to, Sendai viral vectors, adenoviral vectors, adeno-associated virus vectors, retroviral vectors, lentiviral vectors, and the like.
[0168] Ranges: throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity' and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example. I, 2, 2.7, 3. 4, 5, 5.3. and 6. This applies regardless of the breadth of the range.
[0169] Description
[0170] The present invention is based on the observations described herein that the genetic abnormalities that result in clinical disorders known as Dent disease type I can beAtorney Docket Number: 205286-7011W01(00115)
[0171] treated by providing therapeutic vectors comprising nucleic acids encoding functional replacements for the abnormal genes and that long-term expression of these functional replacements can be enhanced by co-administration with an immune modulator. In certain embodiments the therapeutic vectors comprise lentiviral vectors or vectors based on lentiviruses. In certain other embodiments, the therapeutic vectors comprise adeno-associated virus (AAV) vectors or vectors based on AAV vectors. As such, in some aspects, the invention includes methods for treating Dent disease in a subject in need thereof, said method comprising administering to the subject an effective amount of a nucleic acid vector encoding a CLCN5 protein, also known as C1C-5 protein, or a protein product encoded by a CLCN5 gene and an immune modulator, thereby treating the disease. In certain embodiments, the invention also includes viral vectors comprising nucleic acid vectors encoding CLCN5 or C1C-5 protein. In certain embodiments, the immune modulator is an mTor inhibitor. In certain embodiments, the mTor inhibitor is rapamycin. In certain embodiments, the immune modulator is comprised within, attached to, or associated with a lipid nanoparticle (LNP). In certain embodiments, the immune regulator is comprised within, attached to, or associated with a polymer nanoparticle similar to the polymers used in ImmTOR™.
[0172] Dent Disease
[0173] Dent disease is a kidney disorder characterized by the secretion of large amounts of small proteins and calcium ions into the urine, kidney calcifications, kidney stones, and chronic kidney disease. Advanced forms of the disease can result in kidney failures. Dent disease is X-linked, resulting in most patients being male; however, heterozygous females may suffer milder forms of the disease presumably due to random X inactivation in kidney tissues. Symptoms of Dent disease usually appear in childhood; however, mild cases may remain undetected until adulthood. In some cases, the disorder will progressively worsen over time leading to chronic kidney disease and renal failure, typically by 30 to 50 years of age.
[0174] Dent disease is subdivided into two types. Type I Dent disease is characterized by solely by the aforementioned kidney symptoms, while Type 2 Dent disease is characterized by the same kidney symptoms usually accompanied by other developmental disorders including mild intellectual disability, eye involvement or diminished muscle tone (hypotonia). Type I Dent disease is caused by mutations in the CLCN5 gene, whileAtorney Docket Number: 205286-7011W01(00115)
[0175] Type 2 Dent disease is caused by mutations in the OCRL1 gene, which are both located on the X chromosome. These mutations may be inherited or can occur randomly with no previous family history.
[0176] Type I Dent disease, also known as Dent disease Type I or DD1 is a proximal tubular disorder caused by mutations in the CLCN5 gene, which encodes a chloride voltage-gated channel known as CLCN5 or C1C-5 that is most highly expressed in the cells of the renal proximal tubule. About 530 different types of CLCN5 mutations have been described. The CLCN5 or C1C-5 protein plays an important role in receptor-mediated endocytosis in renal proximal tubule epithelial cells. Notably, its deficiency impairs the ability of the proximal tubules to reabsorb small molecular proteins, water, and calcium filtered into the urine, which ultimately causes proteinuria, hypercalciuria, nephrocalcinosis and nephrolithiasis, the first tw o being the hallmark symptoms of Type I Dent disease. Most t pe I Dent disease patients develop life-threatening end-stage renal disease between the ages of 30 and 50 years old. Like other renal tubular disorders, no cure is currently available for type I Dent disease, except for supportive treatments that confer increasingly toxic side effects and cannot stop progress of the disease. Thus, in certain embodiments, the current invention includes methods for treating Dent disease that comprise providing functional copies of the CLCN5 gene and CLCN5 or C1C-5 protein to affected tissues. In certain embodiments, the CLCN5 or C1C-5 protein is delivered by w ay of a nucleic acid vector encoding the CLCN5 or C1C-5 protein.
[0177] Gene Transfer Systems and Vectors
[0178] Gene transfer systems, such as those described in the present invention, depend upon a vector or vector system to shuttle the genetic constructs into target cells. Methods of introducing a nucleic acid into target cells and tissues include physical, biological and chemical methods. Physical methods for introducing a polynucleotide, such as RNA, into a target cell include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like. RNA can be introduced into target cells using commercially available methods which include electroporation (Amaxa Nucleofector-II (Amaxa Biosystems, Cologne, Germany)), (ECM 830 (BTX) (Harvard Instruments, Boston, Mass.) or the Gene Pulser II (BioRad, Denver, Colo.), Multiporator (Eppendort, Hamburg Germany). RNA can also be introduced into cells using cationicAtorney Docket Number: 205286-7011W01(00115)
[0179] liposome mediated transfection using lipofection, using polymer encapsulation, using peptide mediated transfection, or using biolistic particle delivery systems such as “gene guns” (see, for example, Nishikawa, et al. Hum Gene Ther., 12(8): 861 -70 (2001).
[0180] Chemical means for introducing a polynucleotide into a target cell include colloidal dispersion systems, such as macromolecule complexes, nano capsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. An exemplary' colloidal system for use as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle).
[0181] Lipids suitable for use can be obtained from commercial sources. For example, dimyristyl phosphatidylcholine (“DMPC”) can be obtained from Sigma, St. Louis, MO: dicetyl phosphate (“DCP”) can be obtained from K & K Laboratories (Plainview, NY); cholesterol (“Choi”) can be obtained from Calbiochem-Behring; dimyristyl phosphatidylglycerol (“DMPG”) and other lipids may be obtained from Avanti Polar Lipids, Inc. (Birmingham, AL). Stock solutions of lipids in chloroform or chloroform / methanol can be stored at about -20°C. Chloroform is used as the only solvent since it is more readily evaporated than methanol. “Liposome” is a generic term encompassing a variety’ of single and multilamellar lipid vehicles formed by the generation of enclosed lipid bilayers or aggregates. Liposomes can be characterized as having vesicular structures with a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers (Ghosh et al., (1991) Glycobiology 5: 505-10). However, compositions that have different structures in solution than the normal vesicular structure are also encompassed. For example, the lipids may assume a micellar structure or merely exist as nonuniform aggregates of lipid molecules. Also contemplated are lipofectamine-nucleic acid complexes.
[0182] Lentiviral vectors
[0183] Biological methods for introducing polynucleotides of interest into a host cell include the use of DNA and RNA vectors. Viral vectors, and especially7lentiviral vectors,Atorney Docket Number: 205286-7011W01(00115)
[0184] have become the most widely used method for inserting genes into mammalian, e.g., human cells. Viral vectors can be derived from lentivirus, poxviruses, herpes simplex virus I, adenoviruses and adeno-associated viruses, and the like. See, for example, U.S. Pat. Nos. 5,350,674 and 5,585.362. Lentiviral vectors offer the advantage of integrating the payload nucleic acid into the target host cell’s DNA. In this way. the transgene is maintained in the host cell’s genome even after multiple replication and cell division cycles. As such lentiviral vectors are useful in achieving long-term transduction of rapidly dividing host cells. In certain embodiments of the current invention, lentiviral vectors are used to introduce transgene payloads encoding CLCN5 protein into the kidney tissues of neonate or pediatric subjects in order to achieve long-term expression of functional CLCN5 protein complexes. This strategy is desirable because in mammals, the kidneys undergo rapid growth until early adulthood (e.g. around 22 years of age in humans).
[0185] In certain embodiments, the invention includes nucleic acid vectors which encode a CLCN5 protein. In certain embodiments, the nucleic acid vectors are lentiviral vectors. Lentiviral vectors are useful for transducing a target cell with a nucleotide payload. Once within the cell, the RNA genome of the vector is reverse transcribed into DNA and integrated into the genome of the target cell. Lentiviral vectors are part of a larger group of retroviral vectors. A detailed list of lentiviruses may be found in (Coffin et al. (1997) “Retroviruses” Cold Spring Harbor Laboratory Press, pp 758-763).
[0186] Lentiviruses can be divided into primate and non-primate groups. Examples of primate lentiviruses include but are not limited to human immunodeficiency virus (HIV), and simian immunodeficiency virus (SIV). The non-primate lentiviral group includes the prototype “slow virus” visna / maedi virus (VMV), as well as the related caprine arthritisencephalitis virus (CAEV), equine infectious anaemia virus (EIAV) and the more recently described feline immunodeficiency virus (FIV) and bovine immunodeficiency virus (BIV). Lentiviruses differ from other members of the retrovirus family in that lentiviruses have the capability to infect both dividing and non-dividing cells, which make them attractive vectors for in vivo gene therapies (Lewis et al (1992) EMBO J 11 (8):3053-3058) and Lewis and Emerman (1994) J Virol 68 (1):510-516).
[0187] The basic structure of retrovirus and lentivirus genomes share many common features such as a 5' LTR and a 3' LTR, between or within which are located a packagingAtorney Docket Number: 205286-7011W01(00115)
[0188] signal to enable the genome to be packaged, a primer binding site, integration sites to enable integration into a host cell genome and gag, pol and env genes encoding the viral particle components.
[0189] In the provirus, or the nucleic acid molecule of the vector that integrates into the target cell genome, the viral and payload genes are flanked at both ends by regions called long terminal repeats (LTRs). The LTRs are responsible for proviral integration and transcription. LTRs also serve as enhancer-promoter sequences and can control the expression of the viral and pay load genes.
[0190] The LTRs themselves are identical sequences that can be divided into three elements, which are called U3, R and U5. U3 is derived from the sequence unique to the 3' end of the RNA. R is derived from a sequence repeated at both ends of the RNA and U5 is derived from the sequence unique to the 5' end of the RNA. The sizes of the three elements can vary considerably among different viruses.
[0191] In order to render lentiviral vectors incapable of replicating in target cells, most vectors have deletions or mutation in the gag, pol and env genes which render them absent or non-functional. In certain embodiments, the lentiviral vectors of the current invention may comprise one or more of these modifications which make the viral vector replication defective.
[0192] In certain embodiments, the lentiviral vectors of the current invention may be selfinactivating lentiviral vectors. Self-inactivating retroviral vectors comprise deletions of the transcriptional enhancers and / or promoters in the U3 and U5 regions of the LTRs. However, any promoters contained within the transduced DNA sequence between the LTRs in such vectors remains transcriptionally active. This strategy has been employed to eliminate effects of the enhancers and promoters in the viral LTRs on transcription from internally placed genes. Such effects include increased transcription (Jolly et al (1983) Nucleic Acids Res. 11:1855-1872) or suppression of transcription (Emerman and Temin (1984) Cell 39:449-467). This strategy can also be used to eliminate downstream transcription from the 3' LTR into genomic DNA (Herman and Coffin (1987) Science 236:845-848). Such modifications are particularly helpful in lentiviral vectors used for human gene therapy where activation of an endogenous oncogenes is to be avoided.
[0193] Regardless of the method used to introduce the nucleic acid into the cell, a variety of assays may be performed to confirm the presence of the nucleic acid in the cell. SuchAtorney Docket Number: 205286-7011W01(00115)
[0194] assays include, for example, '‘molecular biological” assays well know n to those of skill in the art, such as Southern and Northern blotting, RT-PCR and PCR; “biochemical” assays, such as detecting the presence or absence of a particular peptide, e.g., by immunological means (ELISAs and Western blots) or by assays described herein to identify payload proteins falling within the scope of the invention.
[0195] Adeno-associated virus (AAV) vectors
[0196] In certain embodiments, the vector encoding a CLCN5 protein
[0197] is a viral vector. In certain embodiments, the viral vector is an adeno- associated virus (AAV) vector.
[0198] Adeno-associated viruses are comparatively small, non-enveloped viruses with a ~4 kb genome that is flanked by inverted terminal repeats (ITRs). The genome contains two open reading frames, one of which encodes proteins necessary for replication and the other encodes protein components required for construction of the viral capsid. Wild-type AAV is typically found in the presence of adenovirus, as the adenovirus provides helper proteins that are essential for packaging of the AAV genome into virions. Therefore, AAV production piggybacks on co-infection with adenovirus and relies on three key elements: the ITR-flanked genome, the open-reading frames, and adeno-helper genes. Due to their ability to readily infect human cells without causing apparent disease, AAV is wel I -studied as a vector for gene delivery. Plasmids encoding AAV components may be readily obtained and their use as vectors for gene delivery7has been described in numerous publications, for example. Muzyczka. 1992; U.S. Patent No. 4.797,368, and PCT Publication WO 91 / 18088, all of which are incorporated herein in their entireties by reference. Construction of AAV vectors is also described in a number of publications, including Lebkowski et al., 1988; Tratschin et al., 1985; Hermonat and Muzy czka, 1984; vectors is described in a number of publications, including Lebkowski et al., 1988;
[0199] Tratschin et al., 1985; Hermonat and Muzyczka, 1984.
[0200] AAV-based vector systems typically7separate the viral AAV genes, Adenovirus-derived helper genes, and the transgene payload onto two or three separate plasmids. Three plasmid systems consist of an AAV helper plasmid comprising the rep (replication) and cap (capsid) genes, an adenoviral helper plasmid comprising at least the E2a gene, E4 gene, and VA (viral associated) RNA, and a payload plasmid comprising the transgeneAtorney Docket Number: 205286-7011W01(00115)
[0201] and associated promoters and enhancers flanked by ITR sequences. The helper plasmid or plasmids do not comprise ITRs in order to prevent packaging of a functional, infectious viral genome. Two plasmid systems combine the AAV rep and cap genes and adenoviral helper genes onto a single plasmid and simplify viral vector production by reducing the number of transfected plasmids. Often, a dedicated packaging cell line is used which is engineered to express AAV / helper genes prior to introduction of the payload plasmid.
[0202] In certain embodiments, the plasmid comprising the payload transgene also comprises enhancers and transcriptional activators which precisely control the tissue location and timing of expression of the transgene. In certain embodiments, the transcriptional activator is activated by a tetracycline, doxycycline, anhydrotetracycline, derivative thereof, and / or analogue thereof (generally referred to as “tetracycline agent” herein) and is a so-called “TetON” activator.
[0203] The AAV sequences of the vector typically comprise the cis acting 5' and 3’ inverted terminal repeat sequences (See, e.g., B. J. Carter, in “Handbook of Parvoviruses”, ed., P. Tijsser, CRC Press, pp. 155 168 (1990)). The ITR sequences are about 145 bp in length. In some embodiments, substantially the entire sequences encoding the ITRs are used in the molecule, although some degree of minor modification of these sequences is permissible. The ability to modify these ITR sequences is within the skill of the art. (See, e.g., texts such as Sambrook et al, “Molecular Cloning. A Laboratory Manual”, 2d ed., Cold Spring Harbor Laboratory, New York (1989); and K. Fisher et al., J Virol., 70:520532 (1996)). An example of such a molecule employed in the present invention is a “cis acting” plasmid containing the transgene, in which the selected transgene sequence and associated regulatory elements are flanked by the 5’ and 3’ AAV ITR sequences. The AAV ITR sequences may be obtained from any known AAV, including presently identified mammalian AAV types.
[0204] Thus, the recombinant nucleic acids may comprise inverted terminal repeats (ITR) of an AAV serotypes selected from the group consisting of: AAV1, AAV2. AAV4.
[0205] AAV5, AAV6, AAV6.2, AAV7, AAV8, AAV9, AAV10, AAV1 1, AAV 12, artificial variants such as AAV.RhlO, AAV.rh32 / 33, AAV.rh43, AAV.rh64Rl, rAAV2-retro, AAV-DJ, AAV-PHP.B, AAV-PHP.S, AAV -PHP. eB, or other engineered versions of AAV and variants thereof. The recombinant nucleic acids may also include a promoter operably linked with nucleic acid encoding the transgene payload (e.g. a CLCN5 protein).Atorney Docket Number: 205286-7011W01(00115)
[0206] The promoter may be tissue-specific promoter, a constitutive promoter or inducible promoter.
[0207] Successful gene therapies require efficient infection of target tissues and establishment of long-term gene expression, and previous studies have demonstrated that AAV vectors can successfully infect and transduce a broad variety of cell and tissue types, such as brain, liver, muscle, among others, and have the ability to infect both dividing and quiescent cells. Additionally, AAV-mediated transduction of tissues has been demonstrated to result in long term gene expression greater than 1.5 years in animal models including canine, murine and hamster.
[0208] The tissue tropism of AAV vector particles is influenced by the serotype of the capsid protein, though the receptors and co-receptors that the capsid proteins bind to are often poorly understood and can be expressed by multiple tissue types. For example, AAV2, one of the most well-studied serotypes, has a binding affinity largely for heparan sulfate proteoglycan (HSPG) and as such has a tropism in humans for eye, brain, lung, liver, muscle, and joint tissues. Likewise, AAVs 1, 4, 5, and 6 have a binding affinity’ largely for sialic acid and a tropism for neuronal tissues and AAVs 5,8, and 9 which share a tropism for skeletal muscle cell among other tissues. In this way, the serotype of the AAV capsid protein can be selected to target the payload nucleic acid of the AAV vector to a specific tissue or cell type. Alteration or modification of capsid protein structure can also alter the tissue or cellular tropism and affinity’ of the resulting AAV vector particles.
[0209] It is also contemplated that the invention could be used with any capsid protein capable of selectively binding to skeletal muscle cells, including but not limited to engineered, or otherwise modified, hybrid, or synthetic capsid proteins. In certain embodiments, these engineered capsid proteins can be based on or derived from AAV9 or any other capsid protein with a binding affinity for muscle cells. In certain embodiments, the AAV vectors of the invention can be used with any naturally occurring, modified, hybrid, or engineered AAV capsid protein including, but not limited to AAV1. AAV2. AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV12, AAV-B1, AAV-DJ, AAV-Retro, AAVrh8, AAVrhlO, AAVrh25, Anc80L65, LK03, AAVrhl8, AAVrh74, AAVrh32.33, AAVrh39, AAVrh43, OligoOOl, PHP-B, PHP.eB, and SparklOO among others. The skilled artisan would be able to select an appropriate capsid protein for use with the invention based on the desired target tissue or cell type.Atorney Docket Number: 205286-7011W01(00115)
[0210] Lipid Nanoparticles (LNPs)
[0211] In certain embodiments, the methods and compositions of the present invention include the administration of an immune modulator. In certain embodiments, the immune modulator is formulated or encapsulated or associated with a lipid nanoparticle.
[0212] Non-limiting examples of lipid nanoparticles and methods of making them are described, for example, in Semple et al. (2010) Nat. Biotechnol. 28:172-176; Jayarama et al. (2012), Angew. Chem. Int. Ed., 51: 8529-8533; and Maier et al. (2013) Molecular Therapy 21, 1570-1578. the contents of each of which are incorporated herein by reference in their entirety. Suitable lipid nanoparticle formulations are known in the art, see e.g., U.S. PatentNos. 9,950,065; 10,576,146; 10,485,884; 10,933,127; 10,703,789, and 10,702,600; which are hereby incorporated by reference in their entirety.
[0213] A lipid nanoparticle formulation may be influenced by, but not limited to, the selection of the cationic lipid component, the degree of cationic lipid saturation, the nature of 5 the PEGylation, ratio of all components and biophysical parameters such as size. In one example by Semple et al. (Nature Biotech. 201028:172-176), the lipid nanoparticle formulation is composed of 57.1% cationic lipid, 7.1%
[0214] In certain embodiments, the lipid nanoparticle includes one or more
[0215] cationic lipids (e.g., ionizable cationic lipid), one or more helper lipids, one or more sterols, one or more PEG-modified lipids, or a combination thereof. In certain embodiments, the lipid nanoparticle includes at least one cationic lipid (e g., ionizable cationic lipid), at least one helper lipid, at least one sterol, and at least one PEG-modified lipid. In certain embodiments, the cationic lipid is an ionizable cationic lipid, the helper lipid is a neutral lipid, and the sterol is cholesterol.
[0216] The ionizable cationic lipids, which are pH-sensitive, attract anionic nucleic acids to form the core of self-assembling nanoparticle to ensure high encapsulation. Ionizable lipids are protonated at low pH, which makes them positively charged, but they remain neutral at physiological pH. The pH-sensitivity of ionizable lipids is beneficial for mRNA delivery in vivo, because neutral lipids have less interactions with the anionic membranes of blood cells and, thus, improve the biocompatibility of lipid nanoparticles. This also eliminates a mechanism of toxicity seen with permanently cationic molecules. Trapped in endosomes, in which the pH is lower than in the extracellular environment, ionizableAtorney Docket Number: 205286-7011W01(00115)
[0217] lipids are protonated and, therefore, become positively charged, which may promote membrane destabilization and facilitate endosomal escape of the nanoparticle and / or encapsulated mRNA or other nucleic acid.
[0218] In certain embodiments, a lipid nanoparticle includes about 35 to 45% cationic lipid, about 40% to 50% cationic lipid, about 50% to 60% cationic lipid, or about 55% to 65% cationic lipid. Tn certain embodiments, the cationic lipid is selected from 2,2-dilinoleyl-4-dimethylaminoethyl[l,3]-dioxolane (DLin-KC2-DMA), dilinoleylmethyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-l-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319). Suitable ionizable cationic lipids also include, without limitation, PNI ionizable lipid, SM-102, ALC-0315, DLin-DMA, DLin-D-DMA, DLin-MC3-DMA, DLin-KC2-DMA, DODMA, 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (DMEPC), 1 ,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), l,2-dioleoyl-3-trimethylammonium propane (DOTAP), amino alcohol lipids and combinations thereof. Combinations of any of the foregoing cationic lipids can be used in various ratios.
[0219] Exemplary helper lipids include, but are not limited to, 1,2-distearoyl-sn-glycero-3 -phosphocholine (DSPC), l,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE), l-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholin (POPC) and 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC). In certain embodiments, the LNP includes from about 0.5% to about 15% on a molar basis of the helper lipid e.g., from about 3 to about 12%, from about 5 to about 10% or about 15%, about 10%, or about 7.5% on a molar basis. Examples of helper lipids include, but are not limited to, DSPC, POPC, DPPC, DOPE and SM.
[0220] The LNPs can include a sterol component. For example, a sterol component may be included to confer suitable physicochemical and biological behavior. Such a sterol component may be selected from cholesterol or its derivative e.g., ergosterol or cholesterolhemisuccinate, but it is in certain embodiments cholesterol.
[0221] Cholesterol is often used in lipidic formulations because it is generally recognized that the presence of cholesterol decreases their permeability7and protects them from the destabilizing effect of plasma or serum proteins. In certain embodiments, the sterol is cholesterol. In certain embodiments, the sterol is a cholesterol-PEG conjugate.
[0222] Combinations of any of the foregoing sterols can be used in various ratios. In certainAtorney Docket Number: 205286-7011W01(00115)
[0223] embodiments, the LNP includes from about 5% to about 50% on a molar basis of the sterol 25 (e.g., about 15 to about 45%, about 20 to about 40%, about 40%, about 38.5%, about 35%, or about 31% on a molar basis).
[0224] Exemplary PEG-modified lipids include, but are not limited to, R-3-[(<n-methoxypoly(ethyleneglycol)2000)carbamoyl)]-l,2-dimyristyloxypropyl-3-amine (PEG-c-DOMG or PEG-DOMG), l,2-dimyristoyl-racglycero-3-methoxypolyethylene gly col-2000 (PEG-DMG), PEG2000-DMG, 1,2-Distearoyl-sn-glycerol, methoxypolyethylene glycol (PEG-DSG), 1,2-Dipalmitoyl-sn-glycerol, methoxypolyethylene glycol (PEG-DPG), PEG-cDMA, mPEG-OH. mPEG-AA (mPEG-CM), mPEG-CH2CH2CH2-NH2, mPEG-DMG, mPEG-N,Nditetradecylacetamide (ALC-0159), mPEG-DSPE, and mPEG-DPPE, and combinations thereof (further discussed in Reyes et al., J. Controlled Release, 107, 276-287 (2005), which is hereby incorporated by reference in its entirety).
[0225] Combinations of any of the foregoing PEG-modified lipids can be used in various ratios.
[0226] In certain embodiments, the LNPs include about 0.5% to 20% on a molar basis of the PEG or PEG-modified lipid (e.g., about 0.5 to 10%, about 0.5 to 5%, about 0.5%, about 1.5%, about 3.5%, or about 5% on a molar basis). In certain embodiments, a PEG-modified lipid includes a PEG molecule of an average molecular weight of 2,000 Da. In certain embodiments, a PEG-modified lipid includes a PEG molecule of an average molecular weight of less than 2,000 Da, for example around 1,500 Da, around 1,000 Da, or around 500 Da. The ratio of PEG in the lipid nanoparticle formulations may be increased or decreased and / or the carbon chain length of the PEG lipid may be modified from (e.g., from C14 to C18) to alter the pharmacokinetics and / or biodistribution of the lipid nanoparticle formulations. As a non-limiting example, lipid nanoparticle formulations may contain 0.5% to 3.0%, 1.0% to 3.5%, 1.5% to 4.0%, 2.0% to 4.5%, 2.5% to 5.0%, or 3.0% to 6.0% of the lipid molar ratio of PEG-modified lipid as compared to the cationic lipid, helper lipid and sterol.
[0227] In certain embodiments, the LNP formulation may contain PEG-DMG 2000 (1,2-dimyristoyl-sn-glycero-3-phophoethanolamine-N- [methoxy (polyethylene glycol) -2000). In certain embodiments, the LNP formulation may contain PEG-DMG 2000, a cationic lipid known in the art and at least one other component. In certain embodiments, the LNP formulation may contain PEG-DMG 2000. a cationic lipid known in the art. DSPC and cholesterol. As a non-limiting example, the LNP formulation may containAtorney Docket Number: 205286-7011W01(00115)
[0228] PEG-DMG 2000, DLin-DMA, DSPC and cholesterol. As another non-limiting example, the LNP formulation may contain PEG-DMG 2000, DLin-DMA, DSPC and cholesterol in a molar ratio of 2:40: 10:48 (see, e.g., Geall et al., PNAS, 109(36): 14604-9 (2012); PMID: 22908294).
[0229] In certain embodiments, the lipid nanoparticle contains a lipid mixture in ratios of about 20-70% cationic lipid, 5-45% helper lipid, 20-55% cholesterol, 0.5-15% PEGmodified lipid; such as but not limited to about 20-60% ionizable cationic lipid, about 5-25% helper lipid, about 25-55% sterol, and / or about 0.5-15% PEG-modified lipid. In some certain embodiments, the lipid nanoparticle has a molar ratio of about 20-60% cationic lipid, about 5-25% helper lipid, 25-55% sterol, and 0.5-15% PEG-modified lipid. In certain embodiments, the lipid nanoparticle includes about 25-75% of a cationic lipid, 0.5-15% of ahelper lipid, 5-50% of a sterol, and 0.5-20% of PEG-modified lipid on a molar basis. In certain embodiments, the lipid nanoparticle includes about 35-65% of a cationic lipid, 3-12% of ahelper lipid, 15-45% of a sterol, and 0.5-10% of a PEG-modified lipid on a molar basis.
[0230] In certain embodiments, the lipid nanoparticle has a mean diameter of about 10-500 nm, about 20-400 nm, about 30-300 nm, or about 40-200 nm. In certain nonlimiting embodiments, the lipid nanoparticle has a mean diameter of about 20-100 nm, 40-100 nm, 50-100 nm, 50-150 nm, about 50-200 nm, about 80-100 nm or about 80-200 nm. In certain embodiments, the ratio of lipid to RNA (e.g., mRNA) in a lipid nanoparticle may be 5:1 to 20:1, 10:1 to 25:1, 15:1 to 30: 1 and / or at least 30:1. In some certain embodiments, the ratio of lipid to mRNA in the disclosed lipid nanoparticles is in the range of about 5: 1 to 20: 1, inclusive. In some certain embodiments, the ratio of lipid to mRNA is 6: 1. In certain embodiments, the lipid to mRNA ratio is a molar ratio. For example, in some certain embodiments, the N:P molar ratio of a lipid nanoparticle containing mRNA is 6: 1. The N:P ratio refers to the ratio of positively chargeable polymer amine (N = nitrogen) groups to negatively charged nucleic acid phosphate (P) groups. N:P ratio is an important physicochemical property of polymer-based gene delivery vehicles. The N:P character of a polymer / nucleic acid complex can influence many other properties such as its net surface charge, size, and stability.
[0231] Lipid nanoparticle formulations may be altered by replacing the cationic lipid with a biodegradable cationic lipid which is known as a rapidly eliminated lipid nanoparticleAtorney Docket Number: 205286-7011W01(00115)
[0232] (reLNP). Ionizable cationic lipids, such as, but not limited to, DLinDMA, DLin-KC2-DMA, and DLin-MC3-DMA, have been shown to accumulate in plasma and tissues over time and may be a potential source of toxicity7. The rapid metabolism of the rapidly eliminated lipids can improve the tolerability and therapeutic index of the lipid nanoparticles by an order of magnitude from a 1 mg / kg dose to a 10 mg / kg dose in rat. Inclusion of an enzymatically degraded ester linkage can improve the degradation and metabolism profile of the cationic component, while still maintaining the activity7of the reLNP formulation. The ester linkage can be internally located within the lipid chain, or it may be terminally located at the terminal end of the lipid chain. The internal ester linkage may replace any carbon in the lipid chain.
[0233] The lipids in the LNPs can improve nanoparticle properties, such as particle stability7, delivery efficacy, tolerability and biodistribution. For example, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC). a phosphatidylcholine with saturated tails, has a melting temperature of ~54 °C and a cylindrical geometry that allows DSPC molecules to form a lamellar phase, which stabilizes the structure of lipid nanoparticles. DSPC has been used in the mRNA-1273 and BNT162b2 COVID-19 vaccines. DOPE is a phosphoethanolamine with two unsaturated tails, which has a melting temperature of ~30 °C and a conical shape. DOPE tends to adopt an inverted hexagonal H(II) phase, which destabilizes endosomal membranes and facilitates endosomal escape of lipid nanoparticles.
[0234] Cholesterol can enhance particle stability7by modulating membrane integrity and rigidity. The molecular geometry7of cholesterol derivatives can further affect delivery efficacy and biodistribution of lipid nanoparticles. For example, cholesterol analogues with C-24 alkyd phytosterols increase the in vivo delivery efficacy of LNP-mRNA formulations. Here, the length of the hydrophobic tails of the cholesterol analogues, the flexibility of sterol rings and the polarity of hydroxy groups impact delivery efficacy. PEG-modified lipids can have multiple effects on the properties of lipid nanoparticles. The amount of PEG-modified lipids can affect particle size and zeta potential. PEG-lipids can further contribute to particle stability' by decreasing particle aggregation, and certain PEG modifications prolong the blood circulation time of nanoparticles by reducing clearance mediated by the kidneys and the mononuclear phagocyte system.
[0235] Once they reach target cells, lipid nanoparticles can be internalized by multipleAtorney Docket Number: 205286-7011W01(00115)
[0236] mechanisms, including macropinocytosis and clathrin-mediated and caveolae-mediated endocytosis. The endocytic pathway depends on the properties of the nanoparticle and the cell pe. Following cellular internalization, lipid nanoparticles are usually trapped in endosomal compartments. Thus, endosomal escape is crucial for effective mRNA or other 20 nucleic acid delivery. It is believed that positively charged lipids may facilitate electrostatic interaction and fusion with negatively charged endosomal membranes, resulting in the leak of mRNA or other nucleic acid molecules into the cytoplasm.
[0237] Endosomal escape can be increased by optimizing the pKa values of ionizable lipids. Furthermore, the properties of lipidic tails can affect endosomal escape of lipid nanoparticles. For example, some lipids with branched tails show enhanced endosomal escape compared with their counterparts with linear tails, owing to stronger protonation at endosomal pH. In addition, modulating the type (for example, DSPC and DOPE) and ratio of lipids may improve endosomal escape. See Hou X., et al.. Nat Rev Mater., 1-17. (2021) doi: 10.1038 / s41578-021 -00358-0 for a discussion of the design of lipid nanoparticles for small molecules and nucleic acids and the physiological barriers and suitable administration routes for lipid nanoparticle-mRNA and lipid nanoparticle-small molecule systems.
[0238] Immune Modulators
[0239] In certain embodiments, the therapeutic vectors and pharmaceutical compositions of the current invention are administered with an immune modulator. In certain embodiments, the immune modulator is an immune suppressor that acts to inhibit or suppress immune responses directed against the transgene payload encoded by the therapeutic vectors (e.g. a CLCN5 protein).
[0240] In certain embodiments, the immune modulator is rapamycin, or a derivative or analog thereof. Rapamycin, also known as sirolimus or rapamune, is a macrolide compound that has potent immunosuppressant functions. Rapamycin is an inhibitor of the mammalian target of rapamycin (mTOR) kinase, where its inhibitory action reduces the sensitivity of T cells and B cells to signaling by interleukin-2 (IL-2), which in turn inhibits their activity.
[0241] In certain embodiments, the rapamycin is formulated into a lipid nanoparticle. One non-limiting example of a lipid nanoparticle formulation of rapamycin isAtorney Docket Number: 205286-7011W01(00115)
[0242] ImmTOR™. ImmTOR™ (previously known as SVP-rapamycin) are synthetic, biodegradable nanoparticles comprised primarily of PLA (poly (D, L-lactide) and PLA-PEG [poly (D, L-lactide)-blockpoly(ethylene-glycol)] polymers encapsulating rapamycin. PLA is part of the broader PLGA [poly(lactide-co-glycolide)] family of biodegradable polymers
[0243] that have several decades of successful clinical use and are formulation components in a number of FDA-approved products. PLA- and PLGA-based nanoparticles are hydrolyzed in acidic environments, such as that of the intracellular endosome, and the release of the payload molecule can be tuned for optimal activity in vivo. PLA is hydrolyzed to lactic acid, a natural metabolite that is rapidly cleared. PEG has also been widely studied in clinical trials and is a formulation component in many approved biological products. Use of PLA-based nanoparticle formulations to deliver rapamycin and other immune-modulating drugs has been described previously (Jelonek et al. (2021) Pharmaceutics 13 (11):1881).
[0244] Additional exemplary immunosuppressants include, but are not limited to abatacept; adalimumab; adenosine receptor agonists; anakinra; aryl hydrocarbon receptor inhibitors; autophagy inhibitors, such as 3 -Methyladenine; calcineurin inhibitors; calcineurin inhibitors, such as cyclosporine and tacrolimus; Caspase- 1 inhibitors; certolizumab; cGAS inhibitors; corticosteroids; corticosteroids, such as prednisone, budesonide, prednisolone; cytokine inhibitors; cytokine receptor activators; cytokine receptor inhibitors; etanercept; glucocorticoids; golitnumab; G-protein coupled receptor agonists; G-protein coupled receptor antagonists; histone deacetylase inhibitors; histone deacetylase inhibitors, such as Tnchostatin A; IMDH inhibitors, such as azathioprine, leflunomide, and my cophenolate; infliximab; inhibitors of mitochondrial function, such as rotenone; ixekizumab; kinase inhibitors; Methylprednisolone; monoclonal antibodies, such as basiliximab, daclizumab, and muromonab; mTOR inhibitors, such as rapamycin or a rapamycin analog, sirolimus, and everolimus; natalizumab; NF-K inhibitors, such as 6Bio, Dexamethasone, TCPA-1, IKK VII; OTK3; oxidized ATPs, such as P2X receptor blockers; P38 inhibitors; peroxisome proliferator- activated receptor agonists; peroxisome proliferator-activated receptor antagonists; phosphatase inhibitors; phosphodiesterase inhibitors, such as phosphodiesterase 4 inhibitor (PDE4), such as Rolipram; PI3 KB inhibitors, such as TGX-221; prostaglandin E2 agonists (PGE2), such as Misoprostol;Atorney Docket Number: 205286-7011W01(00115)
[0245] proteasome inhibitor I (PSI); proteasome inhibitors; retinoids; rituximab; secukinumab; statins; TGF-P receptor agonists; TGF- signaling agents; Thymoglobulin; TLR9 antagonists; tocilizumab; ustekinumab; and vedolizumab. Immunosuppressants also include IDO, vitamin D3, cyclosporins, such as cyclosporine A, aryl hydrocarbon receptor inhibitors, resveratrol, azathiopurine (Aza). 6-mercaptopurine (6-MP). 6-thioguanine (6-TG), FK506, sanglifehrin A, salmeterol, my cophenolate mofetil (MMF), aspirin and other COX inhibitors, niflumic acid, estriol and triptolide, interleukins (e.g., IL-1, IL- 10), cyclosporine A, siRNAs targeting cytokines or cytokine receptors and the like.
[0246] Methods of Treatment
[0247] In some aspects, the current invention provides a method for treating Dent disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a therapeutic vector comprising a nucleic acid encoding a CLCN5 protein and an effective amount of an immune modulator, thereby treating the disease. In certain embodiments, the therapeutic vector is a lentiviral vector. In certain other embodiments, the therapeutic vector is a adeno-associated virus (AAV) vector. In certain embodiments, the AAV vector comprises a capsid protein of a serotype selected from the group consisting of AAV 1, AAV2, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV12, AAV-B1, AAV-DJ, AAV-Retro, AAVrh8, AAVrhlO, AAVrh25, Anc80L65, LK03, AAVrhl8, AAVrh74, AAVrh32.33, AAVrh39, AAVrh43, OligoOOl, PHP-B, PHP.eB, and SparklOO. In certain embodiments, the nucleic acid encoding a CLCN5 protein is operably linked to a promoter that drives the expression of the CLCN5 protein. In certain embodiments, the promoter is a constitutive promoter. A non-limiting example of a constitutive promoter that can be used in the therapeutic vectors of the invention is an EF-la promoter. In certain embodiments, the therapeutic vector is a lentiviral vector and comprises the nucleic acid sequence set forth in SEQ ID NO. 1. In certain embodiments, the therapeutic vector and immune modulator are delivered locally to the kidney. In certain embodiments, the local kidney administration is delivered by retrograde ureteral injection. In certain embodiments, the local kidney administration is by ureteroscopy or during a ureteroscopy procedure. In certain embodiments, the immune modulator is rapamycin. In certain embodiments, the immuneAtorney Docket Number: 205286-7011W01(00115)
[0248] modulator is encapsulated by or bound to or associated with a lipid nanoparticle (LNP). One non-binding example of a rapamycin-LNP formulation that would be suitable for use in the invention is ImmTOR™. In certain embodiments, the therapeutic vector and immune modulator are delivered concurrently.
[0249] In some aspect, the current invention provides a method for treating Dent disease in a neonate or pediatric subject in need thereof, the method comprising administering to the subject an effective amount of a lentiviral therapeutic vector comprising a nucleic acid encoding a CLCN5 protein and an effective amount of an immune modulator, thereby treating the disease. In certain embodiments, the nucleic acid encoding a CLCN5 protein is operably linked to a promoter that drives the expression of the CLCN5 protein. In certain embodiments, the promoter is a constitutive promoter. In certain embodiments, the promoter is a constitutive promoter. A non-limiting example of a constitutive promoter that can be used in the therapeutic vectors of the invention is an EF- la promoter. In certain embodiments, the therapeutic vector is a lentiviral vector and comprises the nucleic acid sequence set forth in SEQ ID NO. 1. In certain embodiments, the therapeutic vector and immune modulator are delivered locally to the kidney. In certain embodiments, the local kidney administration is delivered by retrograde ureteral injection. In certain embodiments, the local kidney administration is delivered by ureteroscopy or during a ureteroscopy procedure. In certain embodiments, the immune modulator is rapamycin. In certain embodiments, the immune modulator is encapsulated by or bound to or associated with a lipid nanoparticle (LNP). One non-binding example of a rapamycin-LNP formulation that would be suitable for use in the invention is ImmTOR™. In certain embodiments, the therapeutic vector and immune modulator are delivered concurrently.
[0250] In another aspect, the current invention provides a method for treating Dent disease in an adult subject in need thereof, the method comprising administering to the subject an effective amount of a therapeutic AAV vector comprising a nucleic acid encoding a CLCN5 protein and an effective amount of an immune modulator, thereby treating the disease. In certain embodiments, the nucleic acid encoding a CLCN5 protein is operably linked to a promoter that drives the expression of the CLCN5 protein. In certain embodiments, the promoter is a constitutive promoter. In certain embodiments, the promoter is a constitutive promoter. A non-limiting example of a constitutive promoterAtorney Docket Number: 205286-7011W01(00115)
[0251] that can be used in the therapeutic vectors of the invention is an EF-la promoter. In certain embodiments, the therapeutic vector is a lentiviral vector and comprises the nucleic acid sequence set forth in SEQ ID NO. 1. In certain embodiments, the therapeutic vector and immune modulator are delivered locally to the kidney. In certain embodiments, the local kidney administration is delivered by retrograde ureteral injection. In certain embodiments, the local kidney administration is delivered by ureteroscopy or during a ureteroscopy procedure. In certain embodiments, the immune modulator is rapamycin. In certain embodiments, the immune modulator is encapsulated by or bound to or associated with a lipid nanoparticle (LNP). One non-binding example of a rapamycin-LNP formulation that would be suitable for use in the invention is ImmTOR™. In certain embodiments, the therapeutic vector and immune modulator are delivered concurrently.
[0252] In another aspect, the current invention provides a method for correcting a mutation in the CLCN5 gene in a subject in need thereof, comprising administering to the subject with a therapeutic vector comprising a nucleic acid encoding a CLCN5 protein and a lipid nanoparticle (LNP) comprising an immune modulator. In certain embodiments, the therapeutic vector is a lentiviral vector. In certain embodiments, the therapeutic vector is a AAV vector. In certain embodiments, the AAV vector comprises a capsid protein of a serot pe selected from the group consisting of AAV 1, AAV2, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV12, AAV-B1, AAV-DJ, AAV-Retro, AAVrh8, AAVrhlO, AAVrh25, Anc80L65, LK03, AAVrhl8, AAVrh74, AAVrh32.33, AAVrh39. AAVrh43, OligoOOl, PHP-B, PHP.eB, and SparklOO. In certain embodiments, the nucleic acid vector is operably linked to a promoter that drives expression of the CLCN5 protein. In certain embodiments, the promoter is a constitutive promoter. In certain embodiments, the promoter is an EF-la promoter. In certain embodiments, the lentiviral vector is encoded by the nucleic acid sequence set forth in SEQ ID NO: 1.
[0253] In certain embodiments, the lentiviral vectors, AAV vectors, immune modulators, and compositions of the current invention are delivered locally to the target tissue, including the various parts of the kidney. In certain embodiments, the delivery of the CLCN5 protein is most beneficial when targeted to cells whose normal function depends on the expression of CLCN5 protein. In the kidney, these cells include but are not limitedAtorney Docket Number: 205286-7011W01(00115)
[0254] to epithelial cells lining the proximal tubules and the thick ascending limbs of the Henle loop, and in the intercalated cells of the collecting ducts. In certain embodiments, local administration of the lentiviral vectors, AAV vectors, immune modulators, or compositions of the invention to the kidney is achieved via retrograde ureteral injection or via ureteroscopy or during a ureteroscopy procedure. In this way. the viral particles of the vector have direct contact with the target tissue via the lumen of the renal tubules and ducts. In certain embodiments, the retrograde injection is followed by temporary ligation or partial ligation of the ureter which prevent flushing of the lentiviral particles out of the kidney tissue before they can contact target cells.
[0255] Pharmaceutical
[0256]
[0257] Pharmaceutical compositions of the present invention may comprise as described herein, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents, adjuvants or excipients. Such compositions may comprise buffers such as neutral buffered saline, phosphate buffered saline and the like; carbohydrates such as glucose, mannose, sucrose or dextran, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. Compositions of the present invention are preferably formulated for intravenous administration.
[0258] Pharmaceutical compositions of the present invention may be administered in a manner appropriate to the disease to be treated (or prevented) and the manner or route of administration. The quantity and frequency of administration will be determined by such factors as the condition of the patient, and the type and severity of the patient’s disease, although appropriate dosages may be determined by clinical trials.
[0259] Pharmaceutical compositions of the present invention may be administered in solid or liquid form such as tablets, capsules, powders, solutions, suspensions, emulsions and the like. Pharmaceutical compositions of the present invention may be administered orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by nasal instillation, by implantation, by intracavitary' or intravesical instillation, intraocularly, intraarterially, intralesionally, transdermally, or by the application to mucous membranes. In some embodiments, the composition may be applied to the nose, throat or bronchial tubes, for example by inhalation.Atorney Docket Number: 205286-7011W01(00115)
[0260] Optionally, the methods of the invention provide for the administration of a composition of the invention to a suitable animal model to identify the dosage of the composition(s), concentration of components therein and timing of administering the composition(s), which elicit tissue repair, reduce cell death, or induce another desirable biological response. Such determinations do not require undue experimentation but are routine and can be ascertained without undue experimentation.
[0261] The biologically active agents can be conveniently provided to a subject as sterile liquid preparations, e.g., isotonic aqueous solutions, suspensions, emulsions, dispersions, or viscous compositions, which may be buffered to a selected pH. Lentiviral vectors and agents of the invention may be provided as liquid or viscous formulations. For some applications, liquid formations are desirable because they are convenient to administer, especially by injection. Where prolonged contact with a tissue is desired, a viscous composition may be preferred. Such compositions are formulated within the appropriate viscosity range. Liquid or viscous compositions can comprise carriers, which can be a solvent or dispersing medium containing, for example, water, saline, phosphate buffered saline, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like) and suitable mixtures thereof.
[0262] Sterile injectable solutions are prepared by suspending talampanel and / or perampanel in the required amount of the appropriate solvent with various amounts of the other ingredients, as desired. Such compositions may be in admixture with a suitable carrier, diluent, or excipient, such as sterile water, physiological saline, glucose, dextrose, or the like. The compositions can also be lyophilized. The compositions can contain auxiliary substances such as wetting, dispersing, or emulsifying agents (e.g., methylcellulose), pH buffering agents, gelling or viscosity enhancing additives, preservatives, flavoring agents, colors, and the like, depending upon the route of administration and the preparation desired. Standard texts, such as "REMINGTON'S PHARMACEUTICAL SCIENCE", 17th edition, 1985, incorporated herein by reference, may be consulted to prepare suitable preparations, without undue experimentation.
[0263] Various additives which enhance the stability and sterility' of the compositions, including antimicrobial preservatives, antioxidants, chelating agents, and buffers, can be added. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and theAtorney Docket Number: 205286-7011W01(00115)
[0264] like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin. According to the present invention, however, any vehicle, diluent, or additive used would have to be compatible with the cells or agents present in their conditioned media.
[0265] The compositions can be isotonic, i.e.. they can have the same osmotic pressure as blood and lacrimal fluid. The desired isotonicity of the compositions of this invention may be accomplished using sodium chloride, or other pharmaceutically acceptable agents such as dextrose, boric acid, sodium tartrate, propylene glycol or other inorganic or organic solutes. Sodium chloride is preferred particularly for buffers containing sodium ions.
[0266] Viscosity of the compositions, if desired, can be maintained at the selected level using a pharmaceutically acceptable thickening agent, such as methylcellulose. Other suitable thickening agents include, for example, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, and the like. The choice of suitable carriers and other additives will depend on the exact route of administration and the nature of the particular dosage form, e.g., liquid dosage form (e.g., whether the composition is to be formulated into a solution, a suspension, gel or another liquid form, such as a time release form or liquid-filled form). Those skilled in the art will recognize that the components of the compositions should be selected to be chemically inert.
[0267] It should be understood that the method and compositions that would be useful in the present invention are not limited to the particular formulations set forth in the examples.
[0268] The practice of the present invention employs, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology7, cell biology7, biochemistry7and immunology7, which are well within the purview of the skilled artisan. Such techniques are explained fully in the literature, such as, ‘"Molecular Cloning: A Laboratory Manual”, fourth edition (Sambrook. 2012);
[0269] “Oligonucleotide Synthesis” (Gait, 1984); “Culture of Animal Cells” (Freshney, 2010); “Methods in Enzymology” “Handbook of Experimental Immunology” (Weir, 1997); “Gene Transfer Vectors for Mammalian Cells” (Miller and Calos, 1987); “Short Protocols in Molecular Biology7” (Ausubel, 2002); “Polymerase Chain Reaction: Principles, Applications and Troubleshooting”, (Babar, 2011); “Current Protocols in Immunology”Atorney Docket Number: 205286-7011W01(00115)
[0270] (Coligan, 2002). These techniques are applicable to the production of the polynucleotides and polypeptides of the invention, and, as such, may be considered in making and practicing the invention. Particularly useful techniques for particular embodiments will be discussed herein.
[0271] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the assay, screening, and therapeutic methods of the invention, and are not intended to limit the scope of what the inventors regard as their invention.
[0272] EXPERIMENTAL EXAMPLES
[0273] The invention is further described in detail by reference to the following experimental examples. These examples are provided for purposes of illustration only and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following examples, but rather, should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.
[0274] Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following working examples, therefore, specifically point out the exemplary embodiments of the present invention and are not to be construed as limiting in any way the remainder of the disclosure.
[0275] The material and methods used in the experimental examples are now disclosed. Study Approval and ClC-5 Null Mice. All animal procedures were conducted in accordance with the Guide for the Care and Use of Laboratory7Animals (National Research Council) and were approved by the Institutional Animal Care and Use Committee (IACUC) of Wake Forest University Health Sciences (Protocol numbers: Al 9-053 and A-22-043). Mice were housed in micro-isolator cages under a 12-hour light / dark cycle and provided food and water ad libitum.
[0276] Euthanasia was performed using carbon dioxide (CO2) overdose followed by cervical dislocation. To minimize stress, mice were exposed to CO2 in their home cages.Atorney Docket Number: 205286-7011W01(00115)
[0277] The CO2 flow rate was set to displace 10-30% of the cage volume per minute. Tissues were collected immediately after euthanasia for downstream analyses.
[0278] C1C-5 null mice were generated and maintained as previously describedll. Due to significantly reduced viability of C1C-5 mutant mice in the pure C57BL / 6NJ background, mutant mice were produced by mating heterozygous females (C57BL / 6NJ background) with FVB / NJ males, as reported earlierl 1. Genotyping was performed according to established protocolsl 1.
[0279] DNA Constructs. The ClC-5-expressing AAV shuttle vector, pAAV-hCLCN5, was constructed using the same human EFla promoter and codon-optimized human CLCN5 cDNA as in previously reported lentiviral vector plasmid pCSII-hCLCN511. A human growth hormone polyadenylation (poly A) signal was added downstream of the CLCN5 cDNA to terminate transcription.
[0280] To generate the AAV construct, the Sall-EcoRV fragment of the pAAV-EFla-DIO-EGFP-WPRE-PA plasmid (Addgene Plasmid #37084) was replaced with the Xhol-Hpal fragment from pCSII-hCLCN5. Subsequently, the Spel-Afel fragment was removed to reduce the total size of the DNA between the two inverted terminal repeats (ITRs) to 4.4 kb, optimizing it for AAV packaging.
[0281] AAV Vector Production and Titration. AAV vectors (serotype 9) were packaged using the pAAV-hCLCN5 shuttle vector by VectorBuilder through their Large-scale Packaging and Ultra-purification Service. Viral titers were determined using quantitative PCR (qPCR) 44. Viral DNA was extracted from purified viral particles, and the ITR sequence of AAV2 was used as the target for quantification of viral genome copies. The final titer was 1.03 x 1014genome copies (GC) / mL.
[0282] Percutaneous Intrarenal Injection of Newborn Mice. Intrarenal injections were performed on postnatal day 1, as originally described. Newborn mice were anesthetized using hypothermic anesthesia. All male pups from each litter received injections into both kidneys.
[0283] To access the left kidney, gentle but firm pressure was applied to the left hind limb. The left kidney, located inferior to the spleen on the left lateral side of the abdomen, became visible upon pressure. Using an insulin syringe with a 29G needle (BD UltraFine™), the needle was inserted into the kidney with the tip oriented away from theAtorney Docket Number: 205286-7011W01(00115)
[0284] abdomen. Ten microliters of AAV9-CLCN5 vector (1 *1O10vg / kidney) were slowly injected into the left kidney. The procedure was then repeated for the right kidney.
[0285] Following injection, pups were placed in a cage on a heating pad and monitored for at least 15 minutes to ensure there was no intra-abdominal bleeding. Injected male pups were then returned to their home cage and gently mixed with un-injected female littermates for approximately 3 minutes to facilitate maternal acceptance. Finally, the mother was returned to the cage with all pups and left undisturbed.
[0286] Preparing rapamycin-loaded microspheres. Rapamycin was purchased from Sigma Aldrich. Poly(l-lactide)-co-poly(ethylene glycol) (PLA-PEG) with number average molecular weight (Mn) of PLA = 3000 Da and Mn of PEG = 5000 Da (molar ratio of PEG to PLA: 71:29) was obtained from Nanosoft Polymers (Winston-Salem, NC, USA). Poly(l-lactide) with Mn of 115,000 Da was obtained from Nanosoft Polymers. PVA (98-99% hydrolyzed, low molecular weight; average M.W. 11,000-31.000) was purchased from Sigma- Aldrich (Saint Louis, MO, USA). Microspheres were prepared according to a method described previously. Mixture of PLA and PLA-PEG (50:50 w / w%) was prepared using an oil-in-water emulsion method. Briefly, 110 mg of polymer and 10 mg of rapamycin were dissoLVed in 2 mL of dichloromethane (CH2C12). This polymer-drug mixture was added dropwise to 100 mL of 5% PVA and emulsified using homogenizer at 20,200 rpm for 2.5 min. The resulting emulsion was stirred (100 rpm) overnight with a magnetic stirrer at room temperature for soLVent evaporation. The obtained MS were collected by centrifugation at 12,000 rpm (Eppendorf, Hamburg, Germany; 5810R) for 15 min at 20 °C, washed three times with distilled water, lyophilized and stored at 4 °C.
[0287] Quantifying rapamycin content in microspheres. Rapamycin in 1 mg of microspheres was dissoLVed in 0.5 mL of methylene chloride and stirred with a magnetic stirrer at 500 rpm for 30 min, followed by drug extraction with 0.5 ml ethanol. The samples were stirred for 30 min. centrifuged at 5000 rpm for 15 min, and determine rapamycin content using HPLC, rapamycin standards with known concentrations were run in parallel to determine the amount of rapamycin in microspheres.
[0288] Retrograde Ureteral Injection in Adult Mice. AAV vectors were delivered to the kidneys of adult mice (2-3 months) via retrograde ureteral injection, as previously described. Mice were anesthetized with 3% isoflurane via inhalation. A 2-cm flankAtorney Docket Number: 205286-7011W01(00115)
[0289] incision was made to expose the left kidney, which was gently separated from surrounding adipose tissue. An atraumatic vascular clip (S&T Vascular Clamp, Cat# 00400-03, Fine Science Tools, Heidelberg, Germany) was placed on the ureter below the injection site to prevent leakage into the bladder.
[0290] Using a 30-gauge, 0.5-inch needle connected to a 1 mL syringe. AAV vectors (1 x 1011vgc in 100 pL) were injected into the ureter just below the ureteropelvic junction. After a 15 -minute incubation period, the vascular clip was removed, and the surgical site was closed in two layers — muscle followed by skin — using absorbable 5-0 Vicryl® sutures.
[0291] The same procedure was repeated on the right kidney following closure of the left flank incision. Immediately after surgery and prior to recovery from anesthesia, mice received carprofen (5-10 mg / kg) and buprenorphine SR (0.5-1.0 mg / kg) via subcutaneous injection. Carprofen was administered again at 24- and 48-hours postsurgery. To prevent wound interference, mice were singly housed after the procedure.
[0292] Urine Collection. Urine samples were collected using Hatteras Instruments Model MMC100 Metabolic Mouse Cages (Hatteras Instruments Inc., Cary', NC) over a 16- to 24-hour period. Urine volume was normalized to 24 hours. Following collection, samples were centrifuged at 1,000 x g for 5 minutes to remove particulate matter. Urine volume was measured using a 200 pL pipette.
[0293] Urine Biochemistry. Urinary7calcium concentrations were measured using a colorimetric Calcium Assay Kit (abl02505, Abeam). All urine samples were diluted 10-fold with distilled water prior to assay. Total calcium excretion was calculated by multiplying the measured calcium concentration by the corresponding 24-hour urine volume.
[0294] Total urinary' protein concentration was determined using the Pierce™ BCA Protein Assay Kit (Cat# 23225, Thermo Fisher Scientific). All urine samples were diluted 40-fold with distilled water before analysis. Total protein excretion was calculated by multiplying the protein concentration by7the 24-hour urine volume.
[0295] Urinary' concentrations of beta-2 microglobulin, albumin, and vitamin D-binding protein were measured using the following ELISA kits: Mouse Beta 2 Microglobulin ELISA Kit (LS Bio, LS-F14141-1), Mouse Albumin ELISA Kit (Abeam. ab!08792), and Mouse Vitamin D-binding protein DuoSet ELISA (Bio-Techne, DY4188-05). UrineAtorney Docket Number: 205286-7011W01(00115)
[0296] samples for beta-2 microglobulin and albumin assays were diluted 1:1000 with distilled water prior to analysis. For the vitamin D-binding protein assay, urine samples from wildtype mice were diluted 1:40, while samples from mutant mice were diluted between 1:200 and 1:2000. Total urinary excretion of beta-2 microglobulin, albumin, and vitamin D-binding protein was calculated by multiplying the measured concentrations by the corresponding 24-hour urine volume.
[0297] SDS-PAGE and Western blotting analyses. Urine samples were directly lysed in 2x Laemmli buffer supplemented with protease inhibitors (0.5 mM PMSF and 1 x Complete Protease Inhibitor Cocktail; Roche Diagnostics Corporation, Indianapolis, IN, USA) and phosphatase inhibitors (50 mM NaF, 1.5 mM Na ’Ofi at a 1:1 volume ratio. Kidney tissues were lysed in 1 x Laemmli buffer containing the same protease and phosphatase inhibitors. The antibodies used in this study are listed in Table 2. Protein signals were visualized using chemiluminescence reagents (Thermo Fisher) and detected with the LAS-3000 imaging system (Fujifilm, Tokyo, Japan). Densitometry analysis was done with ImageJ (version 1 54d).
[0298] Immunofluorescence analyses. Kidney tissues were fixed in 4% paraformaldehyde in PBS at 4 °C overnight, then dehydrated and embedded in paraffin. Paraffin-embedded sections (5-8 pm thick) were prepared for histological and immunofluorescence analyses. For immunofluorescence staining, sections were deparaffinized, rehydrated, and blocked with antigen blocking solution. Primary antibodies (see Table 1 for antibodies and fluorescent markers) were applied, followed by incubation with CF594-conjugated secondary antibodies (Biotium, Fremont, CA). For double staining, CF488-labeled secondary antibodies and FITC-labeled lectins were used. After staining, sections were mounted using mounting medium containing DAPI (Vector Laboratories, Burlingame, CA). Images were acquired using the Olympus Slideview VS200 system (Olympus, Japan) and analyzed with Oly via software. Composite images were assembled using Adobe Photoshop, with adjustments including resizing, rotation, and cropping.
[0299] Fluorescence intensity was quantified using NIH ImageJ software (version 1 ,49v).
[0300] Vector DNA Detection. Genomic DNA was extracted from kidney tissues using the DNeasy Blood & Tissue Kit (Qiagen, Germantown, MD). To detect AAV vector DNA, semi-quantitative PCR was performed targeting the codon-optimized hCLCN5Attorney Docket Number: 205286-7011W01(00115)
[0301] sequence within the AAV vector, using primers specific to hCLCN5. Mouse Dmd served as the reference gene. Primer sequences are listed in Table 3.
[0302] RNA Isolation and RT-PCR Analyses. Total RNA was isolated from kidney tissues using the miRNeasy Mini Kit (Cat. No. 217004. Qiagen). Reverse transcription was carried out using the QuantiTect Reverse Transcription Kit (Qiagen). The same primer set used for AAV vector DNA detection was applied for RT-PCR. Ppib cDNA was used as an internal control. RNA samples processed without reverse transcription were included to assess potential genomic DNA contamination.
[0303] Statistical Analysis. Statistical assessments were performed on urinary parameters and immunostaining data using GraphPad Prism (V10) software. Data are presented as median with interquartile range. For analyses comparing two groups, Mann-Whitney tests were performed. When more than two groups were compared, Dunn's multiple comparison tests were performed following Kruskal-Wallis tests. Two-way ANOVA was performed when there were two factors. Significance was set at *p < 0.05, **p < 0.01 and ***p< 0.001.
[0304] Table 1: Sequences of vectors, polynucleotides, and proteins used in the invention SEQ Name: Sequence:
[0305] ID NO:
[0306] 1. hCLCN5 gacggatcgggagatctcccgatcccctatggtcgactctcagtacaatctgctctgatgccgcat lenti viral agttaagccagtatctgctccctgcttgtgtgttggaggtcgctgagtagtgcgcgagcaaaattta vector agctacaacaaggcaaggcttgaccgacaattgcatgaagaatctgcttagggttaggcgttttgc gctgcttcgcgatgtacgggccagatatacgcgttgacattgattattgactagttattaatagtaatc aattacggggtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcc cgcctggctgaccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagta acgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttggca gtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcc tggcattatgcccagtacatgaccttatgggactttcctacttggcagtacatctacgtattagtcatc gctattaccatggtgatgcggttttggcagtacatcaatgggcgtggatagcggtttgactcacgg ggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggact ttccaaaatgtcgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtggga ggtctatataagcagcgcgttttgcctgtactgggtctctctggttagaccagatctgagcctggga gctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaagta gtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaa aatctctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccagaggagctctct cgacgcaggactcggcttgctgaagcgcgcacggcaagaggcgaggggcggcgactggtga gtacgccaaaaattttgactagcggaggctagaaggagagagatgggtgcgagagcgtcagtat
[0307]
[0308] taagcgggggagaattagatcgcgatgggaaaaaattcggttaaggccagggggaaagaaaaaAtorney Docket Number: 205286-7011W01(00115)
[0309] atataaataaaacatatagtatgggcaagcagggagctagaacgatcgcagttaatcctggcct gtagaaacatcagaaggctgtagacaaatactgggacagctacaaccatccctcagacaggat cagaagaactagatcattatataatacagtagcaaccctctatgtgtgcatcaaaggatagagat aaaagacaccaaggaagctttagacaagatagaggaagagcaaaacaaaagtaagaccaccg cacagcaagcggccggccgctgatcttcagacctggaggaggagatatgagggacaatggag aagtgaattatataaatataaagtagtaaaaattgaaccattaggagtagcacccaccaaggcaaa gagaagagtggtgcagagagaaaaaagagcagtgggaataggagcttgttcctgggtctgg gagcagcaggaagcactatgggcgcagcgtcaatgacgctgacggtacaggccagacaattat tgtctggtatagtgcagcagcagaacaattgctgagggctatgaggcgcaacagcatctgttgc aactcacagtctggggcatcaagcagctccaggcaagaatcctggctgtggaaagatacctaaa ggatcaacagctcctggggatttggggttgctctggaaaactcattgcaccactgctgtgccttgg aatgctagtggagtaataaatctctggaacagattggaatcacacgacctggatggagtgggac agagaaattaacaattacacaagctaatacactcctaattgaagaatcgcaaaaccagcaagaa aagaatgaacaagaattattggaattagataaatgggcaagtttgtggaattggtttaacataacaa atggctgtggtatataaaatatcataatgatagtaggaggcttggtaggtttaagaatagttttgc tgtactttctatagtgaatagagttaggcagggatattcaccatatcgtttcagacccacctcccaa ccccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagagagagacagag acagatccattcgattagtgaacggatctacaaatggcagtattcatccacaattttaaaagaaaag gggggatggggggtacagtgcaggggaaagaatagtagacataatagcaacagacatacaaa ctaaagaattacaaaaacaaattacaaaaattcaaaattttcgggtttattacagggacagcagaaa tcactttgaataatcaagcttcgtgaggctccggtgcccgtcagtgggcagagcgcacatcgc ccacagtccccgagaagttggggggaggggtcggcaattgaaccggtgcctagagaaggtgg cgcggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttcccgagggtgggggag aaccgtatataagtgcagtagtcgccgtgaacgttctttttcgcaacgggtttgccgccagaacac agglaagtgccglglglggtlcccgcgggcctggcctclttacgggttatggcccltgcgtgcctlg aatactccacctggctccagtacgtgattcttgatcccgagctggagccaggggcgggccttgc gctttaggagccccttcgcctcgtgctgagttgaggcctggcctgggcgctggggccgccgcgt gcgaatctggtggcaccttcgcgcctgtctcgctgctttcgataagtctctagccatttaaaatttttg atgacctgctgcgacgcttttttctggcaagatagtcttgtaaatgcgggccaggatctgcacact ggtatttcggttttggggccgcgggcggcgacggggcccgtgcgtcccagcgcacatgtcgg cgaggcggggcctgcgagcgcggccaccgagaatcggacgggggtagtctcaagctggccg gcctgctctggtgcctggcctcgcgccgccgtgtatcgccccgccctgggcggcaaggctggc ccggtcggcaccagtgcgtgagcggaaagatggccgcttcccggccctgctccagggggctc aaaatggaggacgcggcgctcgggagagcgggcgggtgagtcacccacacaaaggaaagg ggcctttccgtcctcagccgtcgcttcatgtgactccacggagtaccgggcgccgtccaggcacc tcgatagtctggagctttggagtacgtcgtctttaggtggggggaggggttatgcgatggag tttccccacactgagtgggtggagactgaagtaggccagcttggcacttgatgtaattctccttgg aattgccctttttgagtttggatctggtcattctcaagcctcagacagtggtcaaagtttttctc catttcaggtgtcgtgaacacgctaccggtctcgagccaccATGGATTTCCTgGAG GAACCAATACCAGGTGTAGGAACATATGACGATTTCAATA CTATAGACTGGGTGCGAGAGAAATCACGCGATCGAGACAG ACACCGGGAGATCACGAATAAGTCTAAGGAATCTACCTGG GCCCTCATTCACAGTGTGTCAGACGCTTTTAGCGGATGGCT GCTTATGCTTCTGATTGGACTTCTTAGTGGTAGTTTGGCGG GCCTGATAGACATTAGCGCGCACTGGATGACTGATCTTAA AGAAGGCATATGCACGGGGGGATTTTGGTTCAACCACGAA CATTGCTGCTGGAACTCCGAGCATGTGACATTCGAGGAGA
[0310]
[0311] GGGACAAGTGCCCCGAGTGGAATAGTTGGAGCCAACTGATAttorney Docket Number: 205286-7011W01(00115)
[0312] AATTTCTACAGATGAGGGGGCTTTTGCCTATATAGTTAATT ATTTCATGTATGTTTTGTGGGCCCTCCTCTTCGCCTTCCTCG CGGTATCCCTCGTTAAGGTCTTTGCCCCATATGCCTGTGGC TCTGGTATTCCAGAAATAAAAACTATCCTTTCTGGATTTAT AATCAGGGGATATCTGGGCAAGTGGACGTTGGTCATTAAG ACAATCACCCTTGTCCTTGCTGTATCTTCAGGGTTGTCCTT GGGCAAAGAGGGTCCTCTCGTTCACGTAGCTTGCTGCTGT GGGAACATCCTTTGCCATTGTTTCAATAAATATAGGAAGA ACGAAGCAAAGCGCCGAGAAGTTCTGAGCGCAGCAGCGG CCGCAGGTGTCAGTGTTGCCTTCGGGGCTCCTATAGGAGG GGTACTGTTTAGTCTCGAAGAAGTGTCATATTACTTTCCTC TCAAGACACTGTGGAGGTCCTTTTTTGCAGCCCTGGTCGCG GCTTTTACTCTGCGCTCTATTAATCCTTTTGGAAACAGCAG ACTTGTGCTGTTCTACGTCGAATTCCACACCCCGTGGCATT TGTTTGAACTCGTACCCTTTATTTTGCTGGGGATTTTCGGT GGATTGTGGGGTGCTCTGTTCATACGCACTAACATTGCGTG GTGCCGGAAGAGGAAGACTACTCAGTTGGGCAAATACCCA GTTATTGAGGTCCTCGTCGTTACAGCTATCACAGCAATTCT TGCGTTCCCCAACGAGTACACACGGATGTCTACATCCGAA CTGATTAGCGAACTGTTCAATGATTGTGGGCTCTTGGACTC CTCAAAACTGTGCGATTATGAAAATCGATTTAATACATCA AAGGGCGGAGAACTTCCCGATCGGCCGGCTGGAGTGGGA GTATACTCCGCTATGTGGCAGCTGGCGTTGACGCTCATACT CAAAATCGTCATTACCATATTCACTTTTGGAATGAAGATTC CCTCAGGTCTCTTTATCCCTAGTATGGCAGTTGGTGCGATT GCGGGACGGCTCCTGGGCGTTGGCATGGAGCAGCTGGCTT ATTACCATCAGGAGTGGACCGTATTCAATAGCTGGTGCTCT CAGGGCGCTGATTGCATCACACCAGGCCTGTATGCCATGG TAGGCGCTGCTGCTTGTCTTGGAGGGGTGACTAGGATGAC GGTTTCTCTCGTCGTGATAATGTTCGAGCTTACTGGGGGTC TTGAGTACATTGTGCCCCTGATGGCGGCGGCAATGACATC CAAATGGGTGGCGGATGCGTTGGGTAGGGAAGGGATATAC GATGCACATATTCGCCTTAATGGCTACCCATTTTTGGAGGC TAAGGAAGAATTTGCACATAAAACTCTCGCCATGGATGTT ATGAAACCGAGACGAAACGACCCATTGCTTACAGTACTTA CACAGGATTCCATGACCGTTGAGGACGTGGAAACAATAAT ATCTGAAACAACTTATAGTGGCTTTCCCGTCGTCGTATCCC GAGAATCACAAAGGTTGGTAGGATTCGTGCTGCGACGCGA CCTGATCATATCCATAGAAAACGCACGCAAGAAGCAAGAC GGGGTAGTGTCCACGTCTATAATTTATTTCACCGAGCATAG CCCTCCCTTGCCTCCATATACTCCGCCTACACTGAAACTTC GAAACATCCTCGATTTGTCTCCTTTTACAGTAACCGACCTT ACTCCAATGGAAATCGTAGTAGACATATTTAGAAAGCTTG GATTGAGGCAATGCCTGGTTACCCACAACGGTCGGTTGCT CGGGATAATAACGAAGAAGGACGTACTCAAACATATAGC ACAAATGGCAAACCAGGACCCgGATTCAATCTTGTTCAACT AGtctagagttaacatcgagggatcaagcttatcgataatcaacctctggattacaaaattgtga
[0313]
[0314] aagatgactggtatcttaactatgtgctcctttacgctatgtggatacgctgcttaatgccttgtaAttorney Docket Number: 205286-7011W01(00115)
[0315] tcatgctattgctcccgtatggcttcatttctcctccttgtataaatcctggttgctgtctctttatgag gagtgtggcccgtgtcaggcaacgtggcgtggtgtgcactgtgtttgctgacgcaacccccact ggtggggcattgccaccacctgtcagctccttccgggacttcgcttccccctccctatgccac ggcggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgtgggcactgac aatccgtggtgtgtcggggaagctgacgtccttccatggctgctcgcctgtgtgccacctgga ttctgcgcgggacgtcctctgctacgtcccttcggccctcaatccagcggaccttcctcccgcg gcctgctgccggctctgcggcctctccgcgtcttcgccttcgccctcagacgagtcggatctccc tttgggccgcctccccgcatcgataccgtcgagacctggaaaaacatggagcaatcacaagtag caacacagcagctaccaatgctgcttgtgcctggctagaagcacaagaggaggaggaggtggg ttttccagtcacacctcaggtacctttaagaccaatgactacaaggcagctgtagatcttagccact ttttaaaagaaaaggggggactggaagggctaatcactcccaacgaagacaagatatcctgat ctgtggatctaccacacacaaggctacttccctgattggcagaactacacaccagggccagggat cagatatccactgacctttggatggtgctacaagctagtaccagtgagcaagagaaggtagaag aagccaatgaaggagagaacacccgctgttacaccctgtgagcctgcatgggatggatgaccc ggagagagaagtatagagtggaggttgacagccgcctagcattcatcacatggcccgagag ctgcatccggactgtactgggtctctctggttagaccagatctgagcctgggagctctctggctaa ctagggaacccactgctaagcctcaataaagctgcctgagtgctcaagtagtgtgtgcccgtc tgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagg gcccgttaaacccgctgatcagcctcgactgtgcctctagtgccagccatctgttgttgcccct cccccgtgccttccttgaccctggaaggtgccactcccactgtccttcctaataaaatgaggaaat tgcatcgcatgtctgagtaggtgtcatctatctggggggtggggtggggcaggacagcaagg gggaggattgggaagacaatagcaggcatgctggggatgcggtgggctctatggcttctgagg cggaaagaaccagctggggctctagggggtatccccacgcgccctgtagcggcgcattaagcg cggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctc ctttcgctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcggggcat ccctttagggtccgatttagtgcttacggcacctcgaccccaaaaaactgattagggtgatggt cacgtagtgggccatcgccctgatagacggtttttcgccctttgacgtggagtccacgttcttaat agtggactctgtccaaactggaacaacactcaaccctatctcggtctattcttttgatttataaggg attttggggattcggcctatggtaaaaaatgagctgattaacaaaaatttaacgcgaataatct gtggaatgtgtgtcagttagggtgtggaaagtccccaggctccccaggcaggcagaagtatgca aagcatgcatctcaatagtcagcaaccaggtgtggaaagtccccaggctccccagcaggcaga agtatgcaaagcatgcatctcaattagtcagcaaccatagtcccgcccctaactccgcccatcccg cccctaactccgcccagttccgcccatctccgccccatggctgactaatttttttattatgcagag gccgaggccgcctctgcctctgagctattccagaagtagtgaggaggctttttggaggcctagg cttttgcaaaaagctcccgggagcttgtatatccattttcggatctgatcagcacgtgttgacaataa tcatcggcatagtatatcggcatagtataatacgacaaggtgaggaactaaaccatggccaagttg accagtgccgttccggtgctcaccgcgcgcgacgtcgccggagcggtcgagttctggaccgac cggctcgggtctcccgggacttcgtggaggacgactcgccggtgtggtccgggacgacgtga ccctgttcatcagcgcggtccaggaccaggtggtgccggacaacaccctggcctgggtgtgggt gcgcggcctggacgagctgtacgccgagtggtcggaggtcgtgtccacgaacttccgggacgc ctccgggccggccatgaccgagatcggcgagcagccgtgggggcgggagttcgccctgcgc gacccggccggcaactgcgtgcactcgtggccgaggagcaggactgacacgtgctacgagat ttcgattccaccgccgccttctatgaaaggttgggcttcggaatcgtttccgggacgccggctgg atgatcctccagcgcggggatctcatgctggagtctcgcccaccccaacttgttattgcagcta taatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagt tgtggttgtccaaactcatcaatgtatctatcatgtctgtataccgtcgacctctagctagagcttgg cgtaatcatggtcatagctgtttcctgtgtgaaattgttatccgctcacaattccacacaacatacga
[0316]
[0317] gccggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactcacattaatgcgtgAttorney Docket Number: 205286-7011W01(00115)
[0318] cgctcactgcccgcttccagtcgggaaacctgtcgtgccagctgcataatgaatcggccaacg cgcggggagaggcggtttgcgtatgggcgctcttccgcttcctcgctcactgactcgctgcgctc ggtcgtcggctgcggcgagcggtatcagctcactcaaaggcggtaatacggtatccacagaat caggggataacgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaa aaaggccgcgttgctggcgttttccataggctccgcccccctgacgagcatcacaaaaatcgac gctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctggaag ctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgccttctccctcgg gaagcgtggcgctttctcaatgctcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaa gctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgcctatccggtaactatcgtct tgagtccaacccggtaagacacgacttatcgccactggcagcagccactggtaacaggattagc agagcgaggtatgtaggcggtgctacagagtcttgaagtggtggcctaactacggctacactag aaggacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagtggtagctct tgatccggcaaacaaaccaccgctggtagcggtggtttttgttgcaagcagcagatacgcgc agaaaaaaaggatctcaagaagatccttgatctttctacggggtctgacgctcagtggaacgaa aactcacgtaagggatttggtcatgagattatcaaaaaggatctcacctagatcctttaaataa aaatgaagtttaaatcaatctaaagtatatatgagtaaacttggtctgacagttaccaatgcttaatc agtgaggcacctatctcagcgatctgtctattcgtcatccatagttgcctgactccccgtcgtgta gataactacgatacgggagggcttaccatctggccccagtgctgcaatgataccgcgagaccca cgctcaccggctccagattatcagcaataaaccagccagccggaagggccgagcgcagaagt ggtcctgcaactttatccgcctccatccagtctattaattgttgccgggaagctagagtaagtagttc gccagtaatagtttgcgcaacgtgtgccattgctacaggcatcgtggtgtcacgctcgtcgttg gtatggcttcattcagctccggttcccaacgatcaaggcgagttacatgatcccccatgttgtgcaa aaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagtggccgcagtgttatcactc atggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggt gaglactcaaccaagtcaltctgagaataglglatgcggcgaccgagttgctcttgcccggcgtca atacgggataataccgcgccacatagcagaacttaaaagtgctcatcattggaaaacgttcttcg gggcgaaaactctcaaggatctaccgctgttgagatccagttcgatgtaacccactcgtgcaccc aactgatctcagcatcttttactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatg ccgcaaaaaagggaataagggcgacacggaaatgttgaatactcatactcttccttttcaatatat tgaagcattatcagggttatgtctcatgagcggatacatattgaatgtattagaaaaataaacaa ataggggtccgcgcacatttccccgaaaagtgccacctgacgtc hCLCN5 ATGGATTTCCTgGAGGAACCAATACCAGGTGTAGGAACAT cDNA ATGACGATTTCAATACTATAGACTGGGTGCGAGAGAAATC ACGCGATCGAGACAGACACCGGGAGATCACGAATAAGTCT AAGGAATCTACCTGGGCCCTCATTCACAGTGTGTCAGACG CTTTTAGCGGATGGCTGCTTATGCTTCTGATTGGACTTCTT AGTGGTAGTTTGGCGGGCCTGATAGACATTAGCGCGCACT GGATGACTGATCTTAAAGAAGGCATATGCACGGGGGGATT TTGGTTCAACCACGAACATTGCTGCTGGAACTCCGAGCAT GTGACATTCGAGGAGAGGGACAAGTGCCCCGAGTGGAAT AGTTGGAGCCAACTGATAATTTCTACAGATGAGGGGGCTT TTGCCTATATAGTTAATTATTTCATGTATGTTTTGTGGGCCC TCCTCTTCGCCTTCCTCGCGGTATCCCTCGTTAAGGTCTTTG CCCCATATGCCTGTGGCTCTGGTATTCCAGAAATAAAAACT ATCCTTTCTGGATTTATAATCAGGGGATATCTGGGCAAGTG GACGTTGGTCATTAAGACAATCACCCTTGTCCTTGCTGTAT CTTCAGGGTTGTCCTTGGGCAAAGAGGGTCCTCTCGTTCAC
[0319]
[0320] GTAGCTTGCTGCTGTGGGAACATCCTTTGCCATTGTTTCAAAttorney Docket Number: 205286-7011W01(00115)
[0321] TAAATATAGGAAGAACGAAGCAAAGCGCCGAGAAGTTCT GAGCGCAGCAGCGGCCGCAGGTGTCAGTGTTGCCTTCGGG GCTCCTATAGGAGGGGTACTGTTTAGTCTCGAAGAAGTGT CATATTACTTTCCTCTCAAGACACTGTGGAGGTCCTTTTTT GCAGCCCTGGTCGCGGCTTTTACTCTGCGCTCTATTAATCC TTTTGGAAACAGCAGACTTGTGCTGTTCTACGTCGAATTCC ACACCCCGTGGCATTTGTTTGAACTCGTACCCTTTATTTTG CTGGGGATTTTCGGTGGATTGTGGGGTGCTCTGTTCATACG CACTAACATTGCGTGGTGCCGGAAGAGGAAGACTACTCAG TTGGGCAAATACCCAGTTATTGAGGTCCTCGTCGTTACAGC TATCACAGCAATTCTTGCGTTCCCCAACGAGTACACACGG ATGTCTACATCCGAACTGATTAGCGAACTGTTCAATGATTG TGGGCTCTTGGACTCCTCAAAACTGTGCGATTATGAAAATC GATTTAATACATCAAAGGGCGGAGAACTTCCCGATCGGCC GGCTGGAGTGGGAGTATACTCCGCTATGTGGCAGCTGGCG TTGACGCTCATACTCAAAATCGTCATTACCATATTCACTTT TGGAATGAAGATTCCCTCAGGTCTCTTTATCCCTAGTATGG C AGTTGGTGC GATTGCGGGACGGCTC CTGGGC GTTGGC AT GGAGCAGCTGGCTTATTACCATCAGGAGTGGACCGTATTC AATAGCTGGTGCTCTCAGGGCGCTGATTGCATCACACCAG GCCTGTATGCCATGGTAGGCGCTGCTGCTTGTCTTGGAGGG GTGACTAGGATGACGGTTTCTCTCGTCGTGATAATGTTCGA GCTTACTGGGGGTCTTGAGTACATTGTGCCCCTGATGGCGG CGGCAATGACATCCAAATGGGTGGCGGATGCGTTGGGTAG GGAAGGGATATACGATGCACATATTCGCCTTAATGGCTAC CCATTTTTGGAGGCTAAGGAAGAATTTGCACATAAAACTC TCGCCATGGATGTTATGAAACCGAGACGAAACGACCCATT GCTTACAGTACTTACACAGGATTCCATGACCGTTGAGGAC GTGGAAACAATAATATCTGAAACAACTTATAGTGGCTTTC CCGTCGTCGTATCCCGAGAATCACAAAGGTTGGTAGGATT CGTGCTGCGACGCGACCTGATCATATCCATAGAAAACGCA CGCAAGAAGCAAGACGGGGTAGTGTCCACGTCTATAATTT ATTTCACCGAGCATAGCCCTCCCTTGCCTCCATATACTCCG CCTACACTGAAACTTCGAAACATCCTCGATTTGTCTCCTTT TACAGTAACCGACCTTACTCCAATGGAAATCGTAGTAGAC ATATTTAGAAAGCTTGGATTGAGGCAATGCCTGGTTACCC ACAACGGTCGGTTGCTCGGGATAATAACGAAGAAGGACGT ACTCAAACATATAGCACAAATGGCAAACCAGGACCCgGAT TCAATCTTGTTCAACTAG
[0322] hCLCN5 MDFLEEPIPGVGTYDDFNTIDWVREKSRDRDRHREITNKSKE protein STWALIHSVSDAFSGWLLMLLIGLLSGSLAGLIDISAHWMTD LKEGICTGGFWFNHEHCCWNSEHVTFEERDKCPEWNSWSQL IISTDEGAFAYIVNYFMYVLWALLFAFLAVSLVKVFAPYACG SG1PEIKT1LSGF11RGYLGKWTLV1KTITLVLAVSSGLSLGKEG PLVHVACCCGNILCHCFNKYRKNEAKRREVLSAAAAAGVSV AFGAPIGGVLFSLEEVSYYFPLKTLWRSFFAALVAAFTLRSIN PFGNSRLVLFYVEFHTPWHLFELVPFILLGIFGGLWGALFIRTN
[0323]
[0324] IAWCRKRKTTQLGKYPVIEVLVVTAITAILAFPNEYTRMSTSEAttorney Docket Number: 205286-7011W01(00115)
[0325] LISELFNDCGLLDSSKLCDYENRFNTSKGGELPDRPAGVGVY SAMWQLALTLILKIVITIFTFGMKIPSGLFIPSMAVGAIAGRLL GVGMEQLAYYHQEWTVFNSWCSQGADCITPGLYAMVGAA ACLGGVTRMTVSLVVIMFELTGGLEYIVPLMAAAMTSKWVA DALGREGIYDAHIRLNGYPFLEAKEEFAHKTLAMDVMKPRR NDPLLTVLTQDSMTVEDVETIISETTYSGFPVVVSRESQRLVG FVLRRDL11SIENARKKQDGVVSTS1IYFTEHSPPLPPYTPPTLK LRNILDLSPFTVTDLTPMEIVVDIFRKLGLRQCLVTHNGRLLGI ITKKDVLKHIAQMANQDPDSILFN*
[0326] Human ggctccggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgagaagttgggggg EFl alpha aggggtcggcaattgaaccggtgcctagagaaggtggcgcggggtaaactgggaaagtgatgt promoter cgtgtactggctccgcctttttcccgagggtgggggagaaccgtatataagtgcagtagtcgccgt gaacgttctttcgcaacgggtttgccgccagaacacaggtaagtgccgtgtgtggttcccgcgg gcctggcctctttacgggttatggcccttgcgtgccttgaattacttccacctggctccagtacgtga ttctgatcccgagctggagccaggggcgggcctgcgcttaggagcccctcgcctcgtgctg agttgaggcctggcctgggcgctggggccgccgcgtgcgaatctggtggcaccttcgcgcctgt ctcgctgcttcgataagtctctagccatttaaaatttttgatgacctgctgcgacgctttttctggca agatagtcttgtaaatgcgggccaggatctgcacactggtatttcggtttttggggccgcgggcgg cgacggggcccgtgcgtcccagcgcacatgtcggcgaggcggggcctgcgagcgcggcca ccgagaatcggacgggggtagtctcaagctggccggcctgctctggtgcctggcctcgcgccg ccgtgtatcgccccgccctgggcggcaaggctggcccggtcggcaccagttgcgtgagcgga aagatggccgcttcccggccctgctccagggggctcaaaatggaggacgcggcgctcgggag agcgggcgggtgagtcacccacacaaaggaaaggggccttccgtcctcagccgtcgctcatg tgactccacggagtaccgggcgccgtccaggcacctcgattagttctggagcttttggagtacgtc gtctttaggttggggggaggggtttatgcgatggagttccccacactgagtgggtggagactga agttaggccagcttggcacttgatgtaattctccttggaatttgccctttttgagtttggatcttggttca ttctcaagcctcagacagtggttcaaagttttttcttccatttcaggtgtcgtga
[0327] AAV cctgcaggcagctgcgcgctcgctcgctcactgaggccgcccgggcaaagcccgggcgtcgg vector gcgaccttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactc sequence* catcactaggggttcctgcggccgcacgcgtaagctttgcaaagatggataaagttttaaacaga gaggaatcttgcagctaatggaccttctaggtcttgaaaggagtgggaattggctccggtgcccg tcagtgggcagagcgcacatcgcccacagtccccgagaagttggggggaggggtcggcaatt gaaccgglgcctagagaaggtggcgcggggtaaactgggaaagtgatgtcgtgtactggctcc gcctttttcccgagggtgggggagaaccgtatataagtgcagtagtcgccgtgaacgtctttttcg caacgggtttgccgccagaacacaggtaagtgccgtgtgtggttcccgcgggcctggcctcttta cgggttatggccctgcgtgccttgaattactccactggctgcagtacgtgattctgatcccgagc ttcgggttggaagtgggtgggagagtcgaggccttgcgctaaggagccccttcgcctcgtgct gagttgaggcctggcctgggcgctggggccgccgcgtgcgaatctggtggcaccttcgcgcct gtctcgctgctttcgataagtctctagccatttaaaatttttgatgacctgctgcgacgctttttttctgg caagatagtcttgtaaatgcgggccaagatctgcacactggtattcggttttggggccgcgggc ggcgacggggcccgtgcgtcccagcgcacatgttcggcgaggcggggcctgcgagcgcggc caccgagaatcggacgggggtagtctcaagctggccggcctgctctggtgcctggcctcgcgc cgccgtgtatcgccccgccctgggcggcaaggctggcccggtcggcaccagttgcgtgagcg gaaagatggccgctcccggccctgctgcagggagctcaaaatggaggacgcggcgctcggg agagcgggcgggtgagtcacccacacaaaggaaaagggcctttccgtcctcagccgtcgcttc atgtgactccacggagtaccgggcgccgtccaggcacctcgattagttctcgagcttttggagtac gtcgtctttaggttggggggaggggttttatgcgatggagtttccccacactgagtgggtggagac
[0328]
[0329] tgaagttaggccagctggcactgatgtaattctccttggaatttgcccttttgagtttggatcttggtAttorney Docket Number: 205286-7011W01(00115)
[0330] tcattctcaagcctcagacagtggtcaaagttttttctccattcaggtgtcgtgaggtaccggatc ctctagagtcgagccaccATGGATTTCCTgGAGGAACCAATACCAGG TGTAGGAACATATGACGATTTCAATACTATAGACTGGGTG CGAGAGAAATCACGCGATCGAGACAGACACCGGGAGATC ACGAATAAGTCTAAGGAATCTACCTGGGCCCTCATTCACA GTGTGTCAGACGCTTTTAGCGGATGGCTGCTTATGCTTCTG ATTGGACTTCTTAGTGGTAGTTTGGCGGGCCTGATAGACAT TAGCGCGCACTGGATGACTGATCTTAAAGAAGGCATATGC ACGGGGGGATTTTGGTTCAACCACGAACATTGCTGCTGGA ACTCCGAGCATGTGACATTCGAGGAGAGGGACAAGTGCCC CGAGTGGAATAGTTGGAGCCAACTGATAATTTCTACAGAT GAGGGGGCTTTTGCCTATATAGTTAATTATTTCATGTATGT TTTGTGGGCCCTCCTCTTCGCCTTCCTCGCGGTATCCCTCGT TAAGGTCTTTGCCCCATATGCCTGTGGCTCTGGTATTCCAG AAATAAAAACTATCCTTTCTGGATTTATAATCAGGGGATAT CTGGGCAAGTGGACGTTGGTCATTAAGACAATCACCCTTG TCCTTGCTGTATCTTCAGGGTTGTCCTTGGGCAAAGAGGGT CCTCTCGTTCACGTAGCTTGCTGCTGTGGGAACATCCTTTG CCATTGTTTCAATAAATATAGGAAGAACGAAGCAAAGCGC CGAGAAGTTCTGAGCGCAGCAGCGGCCGCAGGTGTCAGTG TTGCCTTCGGGGCTCCTATAGGAGGGGTACTGTTTAGTCTC GAAGAAGTGTCATATTACTTTCCTCTCAAGACACTGTGGA GGTCCTTTTTTGCAGCCCTGGTCGCGGCTTTTACTCTGCGC TCTATTAATCCTTTTGGAAACAGCAGACTTGTGCTGTTCTA CGTCGAATTCCACACCCCGTGGCATTTGTTTGAACTCGTAC CCTTTATTTTGCTGGGGATTTTCGGTGGATTGTGGGGTGCT CTGTTCATACGCACTAACATTGCGTGGTGCCGGAAGAGGA AGACTACTCAGTTGGGCAAATACCCAGTTATTGAGGTCCT CGTCGTTACAGCTATCACAGCAATTCTTGCGTTCCCCAACG AGTACACACGGATGTCTACATCCGAACTGATTAGCGAACT GTTCAATGATTGTGGGCTCTTGGACTCCTCAAAACTGTGCG ATTATGAAAATCGATTTAATACATCAAAGGGCGGAGAACT TCCCGATCGGCCGGCTGGAGTGGGAGTATACTCCGCTATG TGGCAGCTGGCGTTGACGCTCATACTCAAAATCGTCATTAC CATATTCACTTTTGGAATGAAGATTCCCTCAGGTCTCTTTA TCCCTAGTATGGCAGTTGGTGCGATTGCGGGACGGCTCCT GGGCGTTGGCATGGAGCAGCTGGCTTATTACCATCAGGAG TGGACCGTATTCAATAGCTGGTGCTCTCAGGGCGCTGATTG CATCACACCAGGCCTGTATGCCATGGTAGGCGCTGCTGCTT GTCTTGGAGGGGTGACTAGGATGACGGTTTCTCTCGTCGTG ATAATGTTCGAGCTTACTGGGGGTCTTGAGTACATTGTGCC CCTGATGGCGGCGGCAATGACATCCAAATGGGTGGCGGAT GCGTTGGGTAGGGAAGGGATATACGATGCACATATTCGCC TTAATGGCTACCCATTTTTGGAGGCTAAGGAAGAATTTGC ACATAAAACTCTCGCCATGGATGTTATGAAACCGAGACGA AACGACCCATTGCTTACAGTACTTACACAGGATTCCATGA CCGTTGAGGACGTGGAAACAATAATATCTGAAACAACTTA
[0331]
[0332] TAGTGGCTTTCCCGTCGTCGTATCCCGAGAATCACAAAGGTAttorney Docket Number: 205286-7011W01(00115)
[0333] TGGTAGGATTCGTGCTGCGACGCGACCTGATCATATCCAT AGAAAACGCACGCAAGAAGCAAGACGGGGTAGTGTCCAC GTCTATAATTTATTTCACCGAGCATAGCCCTCCCTTGCCTC CATATACTCCGCCTACACTGAAACTTCGAAACATCCTCGAT TTGTCTCCTTTTACAGTAACCGACCTTACTCCAATGGAAAT CGTAGTAGACATATTTAGAAAGCTTGGATTGAGGCAATGC CTGGTTACCCACAACGGTCGGTTGCTCGGGATAATAACGA AGAAGGACGTACTCAAACATATAGCACAAATGGCAAACC AGGACCCgGATTCAATCTTGTTCAACTAGgctgctcgagagatctacg ggtggcatccctgtgacccctccccagtgcctctcctggccctggaagtgccactccagtgccc accagcctgtcctaataaaataagtgcatcatttgtctgactaggtgtcctctataatatatggg gtggaggggggtggtatggagcaaggggcaagttgggaagacaacctgtagggcctgcggg gtctatgggaaccaagctggagtgcagtggcacaatctggctcactgcaatctccgcctcctgg gttcaagcgattctcctgcctcagcctcccgagttgttgggattccaggcatgcatgaccaggctc agctaatttgttttttggtagagacggggttcaccatattggccaggctggtctccaactcctaat ctcaggtgatctacccaccttggcctcccaaattgctgggattacaggcgtgaaccactgctccctt ccctgtcctctgattttgtaggtaaccacgtgcggaccgagcggccgcaggaacccctagtgat ggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcc cgacgcccgggcttgcccgggcggcctcagtgagcgagcgagcgcgcagctgcctgcagg ggcgcctgatgcggtattttctccttacgcatctgtgcggtatttcacaccgcatacgtcaaagcaa ccatagtacgcgccctgtagcggcgcataagcgcggcgggtgtggtggtacgcgcagcgtg accgctacacttgccagcgccTtagcgcccgctcctttcgctttcttcccttcctttctcgccacgtt cgccggctttccccgtcaagctctaaatcgggggctcccttagggttccgatttagtgcttacgg cacctcgaccccaaaaaacttgatttgggtgatggttcacgtagtgggccatcgccctgatagacg gtttttcgccctttgacgltggaglccacgtlctttaatagtggactcttgttccaaaclggaacaaca ctcaacTctatctcgggctattcttttgatttataagggatttgccgattcggcctattggttaaaaa atgagctgatttaacaaaaatttaacgcgaatttaacaaaatataacgttacaatttatggtgcac tctcagtacaatctgctctgatgccgcatagtaagccagccccgacacccgccaacacccgctg acgcgccctgacgggcttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccggg agctgcatgtgtcagaggttttcaccgtcatcaccgaaacgcgcgagacgaaagggcctcgtgat acgcctatttttataggttaatgtcatgataataatggttcttagacgtcaggtggcacttttcgggga aatgtgcgcggaacccctatttgttattttctaaatacatcaaatatgtatccgctcatgagacaat aaccctgataaatgcttcaataatatgaaaaaggaagagtatgagtattcaacatttccgtgtcgcc ctatcccttttgcggcattttgcctcctgttttgctcacccagaaacgctggtgaaagtaaaag atgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatc cttgagagttcgccccgaagaacgttttccaatgatgagcacttaaagttctgctatgtggcgc ggtattatcccgtatgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatga cttggttgagtactcaccagtcacagaaaagcatctacggatggcatgacagtaagagaatatg cagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggac cgaaggagctaaccgctttttgcacaacatgggggatcatgtaactcgcctgatcgtgggaac cggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaa caacgttgcgcaaactattaactggcgaactactactctagcttcccggcaacaataatagactg gatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgc tgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggta agccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaataga cagatcgctgagataggtgcctcactgataagcattggtaactgtcagaccaagttactcatatat actttagattgatttaaaacttcattttaatttaaaaggatctaggtgaagatcctttttgataatctcat
[0334]
[0335] gaccaaaatcccttaacgtgagttttcgtccactgagcgtcagaccccgtagaaaagatcaaaggAttorney Docket Number: 205286-7011W01(00115)
[0336] atcttcttgagatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagc ggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcg cagataccaaatactgtccttctagtgtagccgtagttaggccaccacttcaagaactctgtagcac cgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtctt accgggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggt tcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgag ctatgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcag ggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggtatctttatagtcct gtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcggagcctat
[0337]
[0338] ggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgt *Note that the AAV vector contains the same EFl alpha promoter (SEQ ID NO: 4) and human CLCN5 cDNA (SEQ ID NO: 2), which encodes the same protein (SEQ ID NO: 3) as in the lentiviral vector (SEQ ID NO: 1).
[0339] Table 2. Antibodies and fluorescent markers used in the study
[0340] Company Catalogue Host Dilution Dilution number for WB for IF CLCN5 Polyclonal antibody Proteintech 26812-1- Rabbit 1:1000 1 :500 AP
[0341] vitamin D binding protein Proteintech 16922-1- Rabbit 1:2000
[0342] AP
[0343] Mouse Albumin Polyclonal Themiofisher A90-134P Goat 1:10000 Antibody, HRP Scientific
[0344] beta-2 microglobulin Thermofisher 701250 Rabbit 1:1000 1:500 Scientific
[0345] Beta-actin Sigma A5441 Mouse 1:5000 Mouse IgG, IgM (H+L) Themiofisher 31446 Goat 1:10000
[0346] Cross-Adsorbed Secondary Scientific
[0347] Antibody in WB
[0348] Rabbit IgG (H+L) Cross- Themiofisher 31462 Goat 1:10000 Adsorbed Secondary Scientific
[0349] Antibody in WB
[0350] Lotus Tetragonolobus Lectin Vector FL-1321- 1 :500 (LTL), Fluorescein Laboratories 2
[0351] Peanut Agglutinin, Vector FL-1071 1:500 Fluorescein (PNA) Laboratories
[0352] Aquaporin 1 / AQP1 Antibody Novus NB600- Mouse 1:1000
[0353]
[0354] (1 / A5F6) Biological 749
[0355] Table 3: Sequence of primers used in the study
[0356] Forward primer Reverse primer SEQ Purpose
[0357] ID NOs.
[0358] hCLCN5 5 ’ gaagcaagacggggtagtgtc 5 ’ ggtcggttactgtaaaagga 6 / 7 AAV gDAN and
[0359]
[0360] gacaa cDNA detectionAtorney Docket Number: 205286-7011W01(00115)
[0361] Dmd 5 ’ctcaaatgtctgccacttcc 5 ’cgcaaccttagctcctacc 8 / 9 Internal control for gDNA input Ppib 5 ’tcgtcttggactctttggaa 5 ’agcgctcaccatagatgctc 10 / 11 Control for cDNA
[0362]
[0363] input
[0364] Example 1: Challenges for gene therapy of type I Dent disease (DPI)
[0365]
[0366] Dent disease is caused by the inability of kidney cells to reabsorb nutrients, water, and other materials that have been filtered from the bloodstream. High amounts of proteins and calcium in the kidney filtrate damage the kidney cells and eventually cause the observed symptoms. Although adverse changes in at least two genes (both X chromosome linked and inherited from the mother) can cause this disease, abnormalities in one of the genes (CLCN5 gene) are responsible for 60% of patients (type I Dent’s disease). A wide number of mutations in CLCN5 have been identified with missense, frameshift, and nonsense mutations making up the majority' (see Fig. 1). Currently there are only supportive treatments for Dent’s disease and none of them target the genetic causes of the disease.
[0367] Previous studies have demonstrated gene therapies for type I Dent disease by delivering CLCN5 cDNA into the kidneys of adult CIC-5 null mice with lentiviral vectors (LV) and observed transgene expression and disease improvement for only three months after treatment. Later studies determined that immune responses to the transgene products resulted in a reduction and elimination of their expression in the kidney, a phenomenon also observed in other gene therapy animal studies and clinical trials which used systemic delivery' of therapeutic vectors. Thus, immune response to transgene products remains a major challenge to gene therapy of type I Dent disease.
[0368] Another unresolved issue in developing effective therapies for type I Dent disease is the large number of mutations which cause the disease, including point mutations, which account for one-third of DD1 cases. Since CIC-5 protein forms a homodimer in its mature form, it is unknown whether endogenous, mutated form of CLC-5 would dimerize with exogenous CLC-5 and impair the gene therapy effects. Thus, many researchers theorized that gene therapy may not be a successful strategy for treating DD1 caused by missense mutations.
[0369] Example 2: Uncoupling Mutation in CIC-5 (E211A) Exacerbates Renal Pathology Beyond Gene KnockoutAtorney Docket Number: 205286-7011W01(00115)
[0370] The ClC-5 E211A Mutant Cohort Exhibit Proteinuria
[0371] The ClC-5 E211 A mutant strain was recovered from frozen sperm. When maintained on a pure C57BL / 6NJ background, generation of E211A mutant males was inefficient due to partial embryonic lethality, with only 1 mutant male obtained from 22 total males. This outcome was comparable to that observed in ClC-5 null mutants, in which only 3 mutant males were recovered from 25 males. Despite their low frequency, these mutant males on a pure C57BL / 6NJ background survived to adulthood.
[0372] To overcome the difficulty in obtaining sufficient mutant animals, E211 A heterozygous females on a pure C57BL / 6NJ background were crossed with wild-type males on a pure FVB / NJ background. This breeding strategy yielded male offspring with a mixed genetic background (50% C57BL / 6NJ and 50% FVB / NJ) at the expected Mendelian ratios (50% wild type and 50% mutant males). Because Dent disease type 1 predominantly affects males, only male mutants were included in this study. Wild-type controls were littermates of mutant mice. Unless otherwise specified, all animals analyzed were on this mixed genetic background.
[0373] At one month of age, both E211 A mutant mice and ClC-5 null mice exhibited normal total urinary' protein levels, as assessed by the bicinchoninic acid (BCA) assay (Table 4). Urinary calcium excretion in both mutant strains was increased by 60-90% compared with wild-type mice. In contrast, ClC-5 null mice previously maintained on a mixed genetic background (25% C57BL / 6NTac, 25% C57BL / 6J, and 50% FVB / NJ) exhibited approximately four- and fivefold increases in total urinary' protein and calcium excretion, respectively. These observations suggest that the phenotypes of ClC-5 null mice became attenuated following prolonged marntenance of female carriers on a pure C57BE / 6NJ background. In the present study, both E211 A and ClC-5 null mutant mice shared the same genetic background (50% C57BL / 6J and 50% FVB / NJ) and showed no differences in total urinary protein or calcium excretion at this early age.
[0374] In contrast, analysis of urinary low-molecular-weight proteins characteristic of Dent disease type 1 revealed marked abnormalities. EUISA assays demonstrated that one-month-old ClC-5 E211 A and ClC-5 null mutant mice from both strains excreted substantially elevated levels of p2-microglobulin and vitamin D-binding protein, with urinary p2-microglobulin increased by more than 75 -fold and vitamin D-binding protein increased by more than 200-fold relative to age-matched wild-type mice (Table 4).Atorney Docket Number: 205286-7011W01(00115)
[0375] Urinary albumin excretion was also increased by approximately 100%. The increase in these low-molecular-weight urinary proteins was evident in both 24-hour excretion and when normalized to creatinine (Table 4). No significant differences in the excretion of 2-microglobulin, vitamin D-binding protein, or albumin were observed between the two mutant strains.
[0376] Table 4: Body weight, diuresis, urinary albumin and urinary calcium of wildtype, E211A and gene knockout mutants (1-month-old)
[0377] Wild type E211A C1C-5 Null E211A~Null Body weight (kg xlO'3) 23.5 ± 0.2 23.1 ± 0.9 26.8± 0.5$$s### Diuresis (ml / 24hrs) 1.7 (1.2 - 2.2) 1.8 (1.4 - 2.7) 1.6 (0.9 - 1.7) ns Diuresis (ml / 24hrs / kg body) 83 (74.7 - 106) 75.6 (634 - 136) 92 (72.1 - 110) ns BCA Total protein (mg / 24hrs) 32.2 (23.1 - 47.4) 29.5 (18.7 - 54.2) 32 (20.1 - 37.9) ns BCA Total protein (mg / 24hrs / kg 1 3 (07 - 1 8) 1 (07 - 1 6) 1 (07 - 1 2) ns body xlO3)
[0378] Calcium concentration (mg / dL) 13.4± 3.4 17.8 ± 6.2 20.9 ± 7.1$ns Calcium (mg / 24hrs) 0.3 ± 0.1 0.6 ± 0.3* 0.5 ± 0.3 ns Calcium (mg / 24hrs / kg body) 11.1 ± 4.1 18.6 ± 9.9 14.8 ± 8.5 ns Calcium / Creatinine (mg / g) 189 ± 34.5 359 ± 98.6*** 300 ± 93.3wns P2-microglobulin concentration 03 (03 -0.4) 19.9 (6.8 - 34.2)*** 25 (16 1 - 56)$$sns (mg / dL xlO)
[0379] P2-microglobulin (mg / 24hrs xlO’ 0.5 (0.3 - 0.7) 40.4 (14.2 - 76.6)** 35.4 (12.9 - 71.6)$ns3)
[0380] P2-microglobulin (mg / 24hrs / kg 17.9 (11 - 26.6) 1040 (432 - 2047)* 1079 (456 - ns body xlO'3) 1960)m
[0381] P2-microglobulin / Creatinine 0.4 (0.3-0.7) 40.7 (21.3-76.9)*** 39.6 (259- ns (mg / g) 73.6)mDBP / Creatinine (mg / g) 0.09 (0.07-0.1) 33.7 (22.1-46.9)*** 27.6 (19.4- ns
[0382] 34
[0383]
[0384] Albumin / Creatinine (mg / g) 45.8 (275-77) 122 (79.9-186)** 143 (109-180)mns Notes: Data are presented as mean ± SD or as median with 95% confidence interval. Sample size: N = 10-19. Statistical significance is indicated as follows: E211A vs. wild type: p < 0.05 (*), p < 0.01 (**). p < 0.001 (***); C1C-5 null vs. wild type: p < 0.05 ($), p < 0.01 ($$), p < 0.001 ($$$); E211A vs. C1C-5 null: p < 0.001 (###') ns: not significant. Statistical tests used: ANOVA with Tukey’s post hoc test for the first four rows, Brown-Forsythe and Welch ANOVA for the remaining rows.
[0385] Age-dependent phenotype changes in C1C-5 E211A Mutant Mice
[0386] At 10-11 months of age, E211A mutant mice exhibited several age-dependent, strain-specific phenotypic changes. First, urinary' p2-microglobulin and vitamin D-binding protein excretion was markedly reduced compared with that in 1-month-old E211 A mutants yet remained significantly elevated relative to age-matched wild-type mice (Table 5, Fig. 13). Notably, P2-microglobulin and vitamin D-binding proteinAtorney Docket Number: 205286-7011W01(00115)
[0387] excretion in C1C-5 null mice did not change with age. Urinary albumin excretion showed no significant differences among genotypes.
[0388] Second, diuresis in 10-11 -month-old E211A mutant mice was significantly higher than that observed in 1 -month-old E211A mutants and exceeded that of age-matched wild-type and C1C-5 null mice (Table 5).
[0389] Third, body weight in E21 1 A mutant mice was reduced relative to age-matched wild-type mice and C1C-5 null mutants at 10 months of age (Table 5) but was unaffected at 1 month of age. Complete loss of C1C-5 did not reduce body weight at 10 months; instead, C1C-5 deficiency increased body weight in young mutant mice (Table 4).
[0390] E211A mutant mice also exhibited increased diuresis and reduced body weight at 18 months of age (Table 6). Urinary biochemical data were not available for 18-month-old mutants, and therefore it remains unclear whether urinary protein excretion changes observed in 10-month-old mutants persist at this age.
[0391] Table 5. Body weight, diuresis and p2-microglobulin excretion of 10- to 11-month mice
[0392] Wild type E211A CIC-5 Null E211A~Null Body weight (kg xlO'3) 48 (47.1-52.4) 41.4 (40.5-48.8)* 45.9 (417-53) ns Diuresis (ml / 24hrs) 27 (1.7-3.5) 5.8 (3.6-79)*** 3.02 (2.9-4.3) # Diuresis (ml / 24hrs / kg body) 542 (37.6- 138 (727- 707 (537-994) #
[0393] 71.7) 181)***
[0394] Calcium concentration (mg / dL) 20.6 (9.5-238) 12.4 (6.9-15.3) 18.3 (9.7-25.4) ns Calcium (mg / 24hrs) 07 (0.2-1.1) 0.9 (07-1.2) 0.8 (0.5-08) ns Calcium (mg / 24hrs / kg body) 13.8 (3.3-208) 22 (13.9-29.8) 15.8 (21.1-19.2) ns Calcium / creatinine (mg / g) 275 (101-367) 422 (256-788) 287 (209-562) ns P2-microglobulin concentration 0.2 (0.1-0.4) 0.6 (0.4-1.3)* 19.6 (2.6-448)$$$# (mg / dL xlO)
[0395] P2-microglobulin (mg / 24hrs xlO'3) 0.5 (0.3-0.9) 4.8 (2.1-10.9)* 58.5 (10.6- ns 1145)sss
[0396] P2-microglobulin (mg / 24hrs / kg body 11.2 (6.9-17) 115 (43.9-248)* 1292 (271- ns xlO'3) 2327)$w
[0397] P2-microglobulin / Crcatininc (mg / g) 0.2 (0.1 -0.9) 3.1 (1.6-4.5)* 24 (8.2-39)s$sns DBP / Creatinine (mg / g) 0.09 (0.04-04) 6.7 (1.6-16.3)* 29.2 (25.5- ns 409)S» Albumin / Creatinine (mg / g) 47.2 (29.6- 84.4 (48.9-126) 138 (42.5-229) ns
[0398]
[0399] 121)
[0400] Notes: Data are presented as median with 95% confidence interval. Sample size: N= 10. Statistical significance is indicated as follows: E211 A vs. wild type: p < 0.05 (*), p < 0.01 (**), p < 0.001 (***); C1C-5 null vs. wild type: p < 0.05 ($), p < 0.01 ($$), p < 0.001 ($$$); E211A vs. C1C-5 null: p < 0.05 (#); ns: not significant. Brown-Forsythe and Welch ANOVA were used for statistical tests.
[0401] Table 3. Body weight and diuresis of 18-month-old mice _ _
[0402] | I Wild type | E211A | CIC-5 Null |E211A~Null|Atorney Docket Number: 205286-7011W01(00115)
[0403] Body weight (kg xlO'3) 50.6 (48.9-54.5) 459 (42.7-47.6)* 55 (47.7-62) ### Diuresis (ml / 24hrs) 22 (09-3 1) 93 (1 4-156)*** 34 (2.2-4.50 ns Diuresis (ml / 24hrs / kg body) 40.1 (21.3-62.5) 199 (307-349)*** 58.1 (42.8-72.2) ns
[0404]
[0405] Notes: Data are presentee as median with 95% confidence interval. Sample size: N= 11- 13. Statistical significance is indicated as follows: E211A vs. wild type: p < 0.05 (*), p < 0.001 (***); E211A vs. C1C-5 null: p < 0.001 (###); ns: not significant. Brown-Forsythe and Welch ANOVA were used for statistical tests.
[0406] ClC-5 E211A. but not ClC-5 null mutant mice, exhibited kidney fibrosis
[0407] Trichrome staining revealed a markedly increased area of interstitial fibrosis in E211A mutants at both 5 and 18 months of age (Fig. 14). In contrast, ClC-5 null mutants showed no significant increase in kidney fibrosis, even at 18 months. Quantification of collagen-positive regions using ImageJ confirmed that E211 A mutants had substantially larger collagen-positive areas (blue regions in trichrome staining) at both time points (Figs. 14B, 14C), whereas ClC-5 null mutants did not. Alizarin Red and von Kossa staining were then used on kidney sections from 18-month-old wild-type and mutant mice of both strains to assess calcium deposition and detected no evident renal calcification.
[0408] Observing glomerular damage in E211A but not ClC-5 null mice
[0409] E211A mutants exhibited clear glomerular abnormalities. At 5 months of age, they had smaller glomeruli (Figs. 15A-15C) and normal glomerular tufts (Fig. 15D). but by 18 months, they developed markedly enlarged Bowman’s spaces (Fig. 15E).
[0410] Glomerular cysts and cysts of unknown origin were also frequently observed in 18-month-old E211A mutants (Fig. 15F).
[0411] To further assess glomerular injury, kidney sections were stained for Wilms tumor protein, a transcription factor and podocyte marker. E211A mutants at 18 months showed reduced Wilms tumor protein expression and fewer Wilms tumor protein-positive cells per glomerulus compared with age-matched wild-type (Fig. 16). ClC-5 null mice exhibited an intermediate number of Wilms tumor protein-positive cells per glomerulus; however, this did not reach statistical significance compared with wild-type or E211 A mutant mice, likely due to substantial intragroup variability and the relatively small sample size. Additionally, E211 A mutants exhibited diminished nephrin expression — a key slit diaphragm component — at both 5 and 18 months. ClC-5 null mutants also showed reduced nephrin expression at 5 months, but this difference was not evident at 18 months.Atorney Docket Number: 205286-7011W01(00115)
[0412] These findings indicate significant impairment of glomerular structure and podocyte integrity in E211 A mutants.
[0413] Tubular degeneration in 18-month-old E211A mutants
[0414] Tubular degeneration was evident in 18-month-old E211A mutants. First, superficial glomeruli were located at the very edge of the kidney capsule, with few or no tubules surrounding them (Fig. 17). Second, tubules were absent around glomeruli with markedly enlarged Bowman’s spaces. These abnormalities were not observed in wildtype mice, C1C-5 null mutants, or 5-month-old E211 A mutants.
[0415] It was noted that the depth of superficial glomeruli from 5-month-old E211 A mutants were smaller than that of wild type mice (Fig.17B, right image). Similar observation was made in 1-month-old E211A mutants (Fig. 17B, left image), indicating that this is more likely a developmental issue rather than a secondary effect of tubular atrophy.
[0416] In addition, E211 A mutants already displayed reduced nephrin expression at 5 months of age, preceding the onset of overt tubular degeneration. This temporal sequence also suggests that the observed tubular loss may represent a direct consequence of the E211A mutation rather than a secondary effect of tubular injury.
[0417] E211A Mice Exhibit Reduced Kidney ClC-5 Expression
[0418] Immunofluorescence analysis revealed that in wild-type mice, ClC-5 protein signals were detected in the superficial cortex and at the corticomedullary junction, with prominent localization along the luminal rim of renal tubules (Fig. 18, left). In ClC-5 null mice, staining was absent, with minimal background signal. In contrast, E211 A mutant mice exhibited weak signals in the superficial cortex but not at the corticomedullary junction. Distinct luminal rim staining was not observed, and the weak signals were diffuse and cytoplasmic in appearance rather than characteristic of typical apical membrane localization of ClC-5.
[0419] The ClC-5 antibody immunogen corresponds to amino acids 697-755 of ClC-5 (NP_001230691, 816 aa), a region that shares 63% and 58% sequence identity with C1C-3 (818 aa) and C1C-4 (747 aa), respectively. Although weak cross-reactivity with C1C-3 or C1C-4, two proteins also expressed in the kidney, cannot be completelyAtorney Docket Number: 205286-7011W01(00115)
[0420] excluded, both proteins show similar prominent apical membrane staining patterns as C1C-5. Therefore, the weak cytoplasmic signals observed in C1C-5 E211A kidneys are unlikely to originate from C1C-3 or C1C-4 and instead most likely reflect mis localized C1C-5 E211A protein.
[0421] Notably, previous studies reported comparable expression levels of E211 A and wild-type C1C-5 in mice maintained on a mixed C57BL / 6-129 / SvJ genetic background4, suggesting that genetic background may influence C1C-5 E211A protein stability or expression.
[0422] To assess whether mis localized and dysfunctional C1C-5 E211A protein induces oxidative stress, kidney sections were stained for oxidative stress markers, including 4-hydroxynonenal and nitrotyrosine. No increase in staining was observed in E211 A kidneys, suggesting that oxidative stress does not play a major role in the renal pathology observed in these mice.
[0423] In total, the studies disclosed herein demonstrate that the C1C-5 E211 A uncoupling mutation produces more severe renal pathology than complete loss of C1C-5. E211 A mutants exhibited progressive interstitial fibrosis, glomerular cysts, and marked podocyte loss at 18 months — features absent in C1C-5 null mice. Whereas C1C-5 null mice maintained or even increased body weight when young, E211A mutants showed significant weight reduction at 10 and 18 months, suggesting systemic consequences of chronic kidney dysfunction.
[0424] Example 3: Rapamycin treatment enables long-lasting gene therapy effects in DPI gene therapy
[0425] Previous studies have demonstrated that lentiviral-based DD1 gene therapies fail to maintain transgene expression and therapeutic effects over three months after administration (Yadav. M. K. et al. (2022) Mol Ther Methods Clin Dev 27, 149-166). Systemic delivery of nanoparticle-encapsulated rapamycin (ImmTOR™) has been reported to induce immunotolerance and cause prolonged transgene expression in other gene therapies (see lyinskii, P. O. et al. (2021) Sci Adv 7). However, this combination strategy has not been used for local, tissue-specific delivery of viral vectors, nor with lentiviral-based (LV) vectors. A series of studies was conducted to investigate whether local delivery of nanoparticle-encapsulated rapamycin (written as rapamycin hereinafterAtorney Docket Number: 205286-7011W01(00115)
[0426] for simplicity) can elongate gene therapy effects in LV-delivered DD1 gene therapy in CLCN5 null mice. Rapamycin nanoparticles (4.5 pg rapamycin / kidney) were codelivered with CLC-5-expressing LV particles (3x107TU / kidney) to the tubules of adult C1C-5 null mice. Following administration, urinary vitamin D binding protein DBP levels were assessed at various timepoints following gene delivery for up to 10 months. It was found that rapamycin co-delivery resulted in low urinary DBP levels remaining low for up to 10 months (the latest time point examined) after LV vector-mediated gene delivery' (Fig. 6). This finding contrasts to the reported loss of gene therapy effects four months following gene delivery which occurs without rapamycin treatment (Yadav, M. K. et al. (2022) Mol Ther Methods Clin Dev 27, 149-166). Thus, local delivery of rapamycin improved the outcome of lentiviral -mediated CLCN5 gene therapy of type I Dent disease.
[0427] Example 4: Matching vectors for successful DPI gene therapy in patients of different ages
[0428] The human kidney grows continuously until adulthood. In adults, the kidney tubular cells are slowly but constantly turned over when aged cells undergo dedifferentiation. Thus, it is unclear whether adeno-associated virus (AAV) vectors, the most common gene delivery vector for in vivo gene therapy, or lentivirus vectors, the integrating vector that maintains long-term expression in dividing cells, is a better vector for delivering DD1 gene therapy to neonates. The studies disclosed herein delivered CLCN5 cDNA via AAV (IxlO10vg / kidney) and LV (3xl06TU / kidney) containing the same CLCN5 expression cassette (controlled by an EFla promoter) to newborn CLCN5 null mice. To avoid possible interference from immune responses, newborn mice were used, since at this early age immune function is incompletely formed. Urinary proteins which are enriched in DD1 patients, including vitamin D binding protein (DBP), CC16, and albumin were then compared by Western blotting. LV-treated mice demonstrated reduced urinary' proteins at 5-, 10-, and 18-months following gene delivery (Fig.2A, only urinary DBP data of 10-month-old mice are shown) whereas AAV -treated mice only showed effects in the first months, and thereafter the effects waned (Fig.2B).
[0429] Accordingly, LV genome could be detected in the kidneys of treated mice 18 mice after delivery.Atorney Docket Number: 205286-7011W01(00115)
[0430] Without wishing to be bound by theory, these data suggest that LV but not AAV vectors are able to achieve long-term transgene expression in tubular cells of newborn animals. Since the human kidneys grow extensively after birth and only stop after the age of 22 years old, these data further suggest that AAV is most likely to be effective for relatively short period when used to deliver gene therapy in neonates.
[0431] Although AAV vectors did not perform well in DD1 gene therapy for neonatal mice, their ability to successfully deliver stable transgene expression in adult mice remained to be investigated, since tubular cells in adult animals possess much lower turnover rates. A series of studies was then conducted which delivered CLCN5-expressing AAV vectors (IxlO11vg / kidney) into the tubules of adult CLCN5 null mice with urinary DBP levels at different time following gene delivery used as a readout for transgene function. Results found that even without rapamycin co-delivery, transgene expression was maintained for at least 10 months (the latest time point examined) after AAV vector-mediated gene delivery, and urinary DBP levels remained low in some treated mice for at least 10 months (the latest time point examined) after AAV vector-mediated gene delivery' (Fig.2), in contrast to loss of gene therapy effects 4 months following LV mediated gene delivery without rapamycin. These data showed that AAV could mediate long-term CIC-5 expression in the proximal tubules of adult mutant mice and result in long-term gene therapy effects.
[0432] Together, these studies reveal that neonatal DD1 gene therapy, lentivirus systems are a better choice than AAV. Without wishing to be bound by theory , this is because the kidneys grow intensively after birth, and AAV genome can be diluted with cell proliferation since they do not integrate into the genome of the host cells. In contrast, lentiviral genomes persist in the host cells as they integrate into the host genome.
[0433] On the other hand, AAV-based vectors are a better choice for treatment of adult patients, since AAV delivered-CLCN5 gene can be expressed for over 10 months even without immune suppression. In addition, AAV vectors are already approved by FDA as a delivery vehicle for several in vivo gene therapies with many more in various stages of development and approval. AAV vectors demonstrate good safety features and thus face lower regulatory hurdles. The finding that AAV vectors cannot maintain transgene expression in the proximal tubules of growing kidneys, dictates that AAV-mediated DD1Atorney Docket Number: 205286-7011W01(00115)
[0434] gene therapy should be delivered after around the age of 22 years old, when the human kidneys lave largely completed their grow th.
[0435] Example 5: Gene therapy is effective in a mouse model of DPI missense mutations One-third of DD1 cases are caused by missense mutations. However, the fact that mature CLCN5 proteins form homodimer complexes make it uncertain whether gene therapy will be effective to these patients, as it would be possible for mutated endogenous protein to pair with exogenous transgene CLCN5 proteins resulting in a sub-functional or non-functional homodimer.
[0436] To test whether gene therapy could be effective for treatment of missense mutations, several studies were conducted in which ClC-5-encoding LV or AAV vectors were administered to adult CLCN5 E211 A (Amino acid 211 was mutated from a Glu to Ala) mutant mice via retrograde ureter injection (~3xl07TU / kidney for LV, IxlO11vg / kidney for AAV). One month following treatment, urinary DBP protein, a urinary protein enriched in DD1 patients, was assessed and found to be reduced in all treated mice. DBP remained at low levels in more than half of the treated animals 10 months after the treatment. The data show that 1) DD1 gene therapy is effective to animals caused by point mutations, and 2) gene therapy in these animals induced less severe immune responses, most likely because the exogenous CIC-5 protein is highly similar to the endogenous CIC-5.
[0437] Example 6: Local rapamycin loaded microsphere co delivery with LV CLCN5 achieved long term gene therapy effects.
[0438] In previous studies disclosed herein, lentiviral (LV) delivery of human CLCN5 cDNA to the kidneys of CLCN5 mutant mice resulted in marked reductions in urinary calcium and protein excretion during the first three months after treatment. However, both urinary calcium and protein levels returned to pretreatment levels approximately four months post-delivery. Subsequent analyses suggested that immune responses against the trans gene product contributed to the loss of therapeutic efficacy. It was therefore asked whether local immune suppression with rapamycin could mitigate these responses and thereby prolong the duration of gene therapy effects.Atorney Docket Number: 205286-7011W01(00115)
[0439] To test this possibility, rapamycin was encapsulated into polymeric microspheres to enable sustained local release. Rapamycin loaded microspheres (4.5 pg rapamycin per kidney) were co delivered with LV CLCN5 vectors (370 ng p24 per kidney, ~3.7 x 107TU per kidney) to increase local rapamycin exposure while minimizing systemic immunosuppression. Mutant mice receiving LV CLCN5 alone served as controls. The rapamycin treated and untreated groups consisted of 10 and 5 mutant mice, respectively. One month after treatment, urinary 02 microglobulin levels were markedly reduced in both LV CLCN5 treated groups compared with age matched untreated mutant mice. In mice treated with LV CLCN5 alone, urinary 02 microglobulin levels were modestly reduced at four months post treatment but returned to baseline levels by eight months (Figs. 6A-6B). In contrast, mice receiving LV CLCN5 together with rapamycin loaded microspheres exhibited sustained reductions in urinary' 02 microglobulin at both four and ten months after treatment (Figs. 6C-6D). The gradual loss of therapeutic effects observed in the absence of rapamycin was consistent with previous findings. Notably, local co delivery of rapamycin microspheres extended LV mediated gene therapy effects for at least ten months.
[0440] For Western blot analyses of urine samples, Coomassie blue staining of SDS PAGE gels was used to verify comparable protein loading. Small proteins in the 15-20 kDa range were equalized across samples, as a stable internal urinary protein control that is unaffected by Dent disease type 1 is not available. In addition, bicinchoninic acid (BCA) assays showed no significant difference in total urinary' protein excretion between wild type and mutant mice in this study.
[0441] Urinary vitamin D-binding protein levels were also examined in control and treated mice and did not observe an evident reduction in LV treated animals, regardless of whether rapamycin microspheres were co delivered (Fig. 10). Potential explanations for this observation are discussed below.
[0442] Rapamycin enhanced CIC 5 expression in the kidney
[0443] To determine whether rapamycin prolonged gene therapy effects by enhancing transgene expression, lentiviral (LV) vector DNA and CLCN5 transgene expression was then examined in the kidneys of mice treated with LV CLCN5 with or without rapamycin loaded microspheres. LV genomic DNA (Fig. 4A) and CLCN5 transgene mRNAAtorney Docket Number: 205286-7011W01(00115)
[0444] (Fig. 4B) were readily detected in the kidneys of treated mice regardless of rapamycin co delivery, indicating comparable vector presence and transcription at the DNA and mRNA levels.
[0445] In contrast, Western blot analysis revealed higher C1C 5 protein expression in mice receiving LV CLCN5 together with rapamycin microspheres compared to mice treated with LV CLCN5 alone (Fig. 4C). Densitometric analysis confirmed a significant increase in C1C 5 protein levels in the rapamycin treated group (Fig. 4D). These findings indicate that local immune modulation with rapamycin enhances C1C 5 protein expression and provide a mechanistic explanation for the sustained reduction in urinary 02 microglobulin observed in rapamycin treated mice.
[0446] Example 7: AAV-mediated CLCN5 gene delivery to neonatal mutant kidneys showed transient therapeutic effects.
[0447] Data from the studies disclosed herein and previously published work demonstrate that lentiviral vectors can achieve long term gene therapy effects in both neonatal and adult mice. Given the established clinical safety7profile of adeno associated virus (AAV) vectors, studies next evaluated whether AAV is a suitable vector for gene therapy of Dent disease type 1. To this end, CLCN5 cDNA was delivered to the kidneys of neonatal mutant mice using an AAV vector.
[0448] AAV9 CLCN5 (1 x 1010vector genomes per kidney) was administered to each kidney of CLCN5 mutant mice via percutaneous intrarenal injection on postnatal day 1. One month after delivery, Western blot analyses of urinary 02 microglobulin and vitamin D-binding protein revealed marked reductions in both proteins in AAV treated mice compared with untreated mutants (Figs. 8A, 8B). ELISA analyses of urinary 02 microglobulin and vitamin D-binding protein further confirmed substantial reductions in both proteins one month after AAV9 CLCN5 treatment (Fig. 5C). However, considerable variability among untreated mutant mice and the limited number of treated animals (n = 4) made it difficult to detect statistically significant differences between untreated and one month post treated groups. Nevertheless, these findings indicate that AAV mediated CLCN5 gene delivery can transiently ameliorate proteinuria in neonatal CLCN5 null mice.Atorney Docket Number: 205286-7011W01(00115)
[0449] In contrast urinary vitamin D-binding protein levels in AAV treated mutant mice increased at 2, 3, and 4 months after treatment (Figs. 5D, 5E). By four months postdelivery, urinary vitamin D-binding protein levels in all four treated mice approached those observed in untreated mutants, and urinary 02 microglobulin levels in two treated mice reached levels comparable to untreated controls (Fig. 5F, 5G). Similar trends were observed in longitudinal ELISA analyses of urinary marker proteins (Fig. 5C).
[0450] Collectively, these data indicate that AAV9 CLCN5 delivery to neonatal mutant mice produces only transient phenotypic improvement, in contrast to the sustained (up to 18 months) therapeutic effects observed following neonatal LV CLCN5 delivery’ in previous studies.
[0451] ELISA analysis of urinary albumin did not reveal an apparent reduction even one month after AAV9 CLCN5 treatment (Fig. 5H), suggesting that albuminuria in CLCN5 mutant mice may arise from mechanisms distinct from those affecting 02 microglobulin and vitamin D-binding protein reabsorption. Urinary calcium excretion was also assessed; however, substantial inter animal variability and the small cohort size precluded detection of consistent treatment related changes (Fig. 51).
[0452] Transgene expression was maintained in the kidneys of mutants treated despite attenuation of therapeutic effects.
[0453] Mouse proximal tubules undergo substantial postnatal growth, with tubule length increasing more than sixfold between postnatal day 21 and two months of age, driven by extensive epithelial cell proliferation. Without wishing to be bound by theory, it was therefore hypothesized that the loss of therapeutic effects observed after neonatal AAV treatment might result from dilution or loss of AAV genomes during this proliferative phase.
[0454] To test this possibility AAV vector DNA and human CLCN5 transgene expression was examined in kidney samples from AAV9 CLCN5-treated neonatal mutant mice. AAV vector DNA was detected in the kidneys of three out of four treated mice (Fig. 6A), whereas human CLCN5 cDNA was detected in all four treated mutants but not in untreated controls (Fig. 6B). Detection of hCLCN5 cDNA was dependent on the presence of reverse transcriptase (RT), as demonstrated by the absence of signal in RT negative control reactions, thereby excluding amplification from residual AAV DNA. TheAtorney Docket Number: 205286-7011W01(00115)
[0455] detection of CLCN5 cDNA in one animal in which AAV vector DNA was not detected is most likely attributable to differences in assay sensitivity or detection parameters between AAV DNA and transgene cDNA analyses.
[0456] Western blot analysis confirmed C1C 5 protein expression in the kidneys of all AAV treated mutant mice, while no C1C 5 expression was observed in untreated mutants (Fig. 6C). Consistent with these findings, immunofluorescence staining demonstrated C1C 5 expression with characteristic localization at the tubular lumen in kidney sections from treated mice (Fig. 6D). Together, these protein expression data were concordant with the transgene mRNA detection results.
[0457] Collectively, these results demonstrate that AAV mediated CLCN5 transgene expression persisted in the kidneys of neonatal treated mutant mice despite the attenuation of therapeutic efficacy over time.
[0458] CIC 5 protein was expressed in proximal tubules despite attenuated therapeutic effects The persistence of transgene expression despite diminished therapeutic efficacy prompted the examination of whether CIC 5 protein was expressed in proximal tubules, the primary nephron segment responsible for protein reabsorption. To assess nephron segment-specific expression following AAV9 CLCN5 delivery, kidney sections were co stained with Lotus tetragonolobus lectin (LTL), peanut agglutinin (PNA), and aquaporin 2 (AQP2), markers of proximal tubules, distal tubules / medullary thick ascending limb, and collecting ducts, respectively.
[0459] Consistent with prior reports describing endogenous CIC 5 localization. CIC 5 expression was detected in LTL positive proximal tubules, PNA positive distal tubules (likely medullary thick ascending limbs), and AQP2 positive collecting ducts (likely a intercalated cells), as shown in Fig. 7 (yellow tubules). Thus, despite the continued presence of CIC 5 protein in proximal tubules — the major site of low molecular weight protein reabsorption — AAV9 CLCN5-mediated gene therapy effects declined over time.
[0460] To further explore whether spatial changes in CIC 5 expression might contribute to the attenuation of therapeutic benefit, studies then compared the distribution of CIC 5-positive tubules in mutant mice at 3 weeks and 4 months following neonatal AAV9 CLCN5 delivery. At 3 weeks post treatment, CIC 5-positive tubules were distributed across both superficial cortical regions and areas near the corticomedullary junction,Atorney Docket Number: 205286-7011W01(00115)
[0461] resembling the expression patern observed in untreated 3-week-old wild type mice (Fig.
[0462] 10). In contrast, at 4 months post treatment, C1C 5 expression was predominantly observed near the corticomedullary junction, with markedly reduced expression in superficial and mid cortical regions. Whether the preferential loss of C1C 5 expression in superficial proximal tubules contributes to the observed decline in therapeutic efficacy remains unclear.
[0463] Taken together, these findings demonstrate that neonatal AAV9 CLCN5 delivery' results in sustained transgene expression across renal tubule segments, including proximal tubules, but induces only transient phenotypic improvement.
[0464]
[0465] 8: Local CLCN5 to the kii CLCN5 mutant mice failed to improve phenotypes despite mediating CIC 5 expression
[0466] Studies next evaluated AAV9 mediated CLCN5 gene delivery in adult C1C5 null mutant mice. AAV serotype 9 was selected based on prior reports demonstrating efficient transduction of renal tubules and robust physiological effects at systemic doses of approximately 6.6 x 1012genome copies (gc) / kg. Accordingly, 1 x 1011gc of AAV9 CLCN5 (the same vector batch used for neonatal studies) was delivered to each kidney via retrograde ureteral injection, corresponding to a dose of ~6.6 x io12gc / kg for mice weighing approximately 30 g.
[0467] Despite successful vector delivery, Western blot analyses of urinary' 02 microglobulin and vitamin D-binding protein performed 1 and 4 months after treatment did not reveal appreciable reductions in either protein compared with untreated mutant mice, regardless of whether rapamycin loaded microspheres were co delivered (Figs. 3A- 3D). Notably, urinary 02 microglobulin exhibited an increased levels 4 months following AAV9-CLCN5 treatment, although the physiological significance of this observation is unclear.
[0468] The absence of phenotypic improvement prompted us to examine whether AAV mediated transgene expression was achieved in adult kidneys. Consistent with findings in neonatal mice, AAV vector DNA was detected in kidneys from 8 of 10 treated adult mutants (Figs. 12A, 12B), and codon optimized human CLCN5 mRNA was detected in all treated mice examined (Figs. 12C, 12D). Furthermore, CIC 5 protein expression wasAtorney Docket Number: 205286-7011W01(00115)
[0469] readily detectable in all treated adult mutant mice 8-10 months after AAV delivery (Figs. 12E, 12F).
[0470] Western blot analyses revealed two C1C 5-immunoreactive bands in wild type kidneys — one at approximately 75 kDa and a second between 100 and 150 kDa — neither of which was detected in untreated mutant mice. Both bands were restored following AAV9 CLCN5 treatment and likely represent specific C1C 5 species. Given that C1C 5 is a glycosylated protein and forms homodimers, the presence of multiple bands may reflect differences in glycosylation status or incomplete denaturation during sample preparation. Co-delivery of rapamycin-loaded microspheres showed a trend toward increased C1C-5 protein expression; however, the difference was not statistically significant owing to large inter-animal variation (Fig. 9E); however, this enhancement did not translate into measurable improvement of urinary phenoty pes.
[0471] Together, these results demonstrate that while AAV9 CLCN5 delivery to adult mouse kidneys mediates persistent transgene expression at the DNA, mRNA. and protein levels, it fails to confer functional improvement of disease associated urinary markers.
[0472] Example 9: Selected discussion
[0473] In the studies disclosed herein, lentiviral and AAV mediated delivery of codon optimized CLCN5 cDNA to neonatal and adult C1C 5-null mice were systematically evaluated, with and without local co delivery of rapamycin loaded microspheres, to define key determinants of effective gene therapy for Dent disease type 1. These findings provide several important insights into vector choice, immune modulation, and age dependent constraints on renal gene therapy.
[0474] First, these studies demonstrate that local co delivery of rapamycin loaded microspheres with lentiviral vectors markedly enhances C1C 5 expression and extends the duration of therapeutic benefit. Mice receiving rapamycin microspheres exhibited increased C1C 5 protein levels and sustained reductions in urinary 02 microglobulin for at least 10 months, the latest time point examined. This contrasts sharply with previous observations that lentiviral CLCN5 delivery alone improved phenotypes for only three months, likely due to immune responses against the transgene product. Without wishing to be bound by theory, it can be hypothesized that the prolonged efficacy observed in the present study results from localized, sustained immune suppression mediated byAtorney Docket Number: 205286-7011W01(00115)
[0475] rapamycin release from the microspheres. While systemically delivered rapamycin loaded nanoparticles (e.g., ImmTOR) have been shown to suppress immune responses to viral vectors and transgene products in other gene therapy contexts, the studies disclosed herein are the first to demonstrate the effectiveness of local delivery of rapamycin loaded microspheres for immune modulation in renal gene therapy. This strategy has clear translational potential, as it enhances gene therapy durability while minimizing systemic immunosuppression and associated side effects.
[0476] It should be noted that lentiviral CLCN5 delivery preferentially reduced urinary' 02 microglobulin but not vitamin D-binding protein. Several factors may contribute to this observation. First, in the current mouse cohorts, Dent disease-like phenotypes were generally milder than those observed previously, likely reflecting background strain differences. Consistent with this, diuresis, total urinary protein excretion (by BCA assay), and urinary calcium excretion were not significantly different between wild type and C1C 5-null mice (Fig. 12), and substantial variability was observed among mutant individuals, limiting statistical power to detect therapeutic effects. Second, 02 microglobulin and vitamin D-binding protein are internalized via distinct receptors but related endocytic pathways. 02 microglobulin binds directly to megalin, whereas vitamin D-binding protein binds to cubilin but requires megalin for internalization. Because C1C 5 deficiency disrupts trafficking of both megalin and cubilin, restoration of vitamin D-binding protein endocytosis may require more complete or spatially precise correction than is needed to restore 02 microglobulin reabsorption.
[0477] Second, it was found that AAV9 mediated CLCN5 delivery to neonatal kidneys resulted in only transient phenotypic improvement. Both urinary 02 microglobulin and vitamin D-binding protein levels were reduced one month after treatment but subsequently returned to elevated levels. This outcome contrasts with earlier neonatal lentiviral delivery studies, in which therapeutic effects persisted for up to 18 months. Without wishing to be bound by theory, the data disclosed herein suggests this difference is due primarily to the non-integrating nature of AAV genomes and the extensive proliferation of proximal tubular epithelial cells during postnatal kidney grow th. Notably, C1C 5 protein expression persisted despite loss of therapeutic benefit, w ith expression maintained predominantly in medullary regions and diminished in superficial and mid cortical regions. One plausible explanation is that the remaining C1C 5-expressing cellsAtorney Docket Number: 205286-7011W01(00115)
[0478] are non-proliferating cells and not those primarily responsible for low molecular weight protein endocytosis. These findings underscore that, for Dent disease type 1, durable therapeutic benefit requires not only sustained transgene expression but also appropriate targeting of the relevant functional cell populations.
[0479] Third, it was observed that AAV9 mediated CLCN5 delivery to adult mutant mouse kidneys failed to improve urinary phenotypes, despite robust and persistent C1C 5 expression in renal tubules, including proximal tubules. One possible explanation is that AAV9 inefficiently transduces the subset of C1C 5-expressing proximal tubular cells responsible for endocytosis of low molecular weight proteins. If so. identification or engineering of alternative AAV capsids with improved tropism for these cells may be critical. Another possibility is that the relevant epithelial cells undergo sufficiently frequent turnover such that episomal AAV genomes cannot be maintained at therapeutically effective levels. The neonatal AAV studies disclosed herein and previously published, which showed dilution of therapeutic effects during periods of rapid tubule growth despite persistent expression, provide indirect support for this latter mechanism. If episomal instability proves to be the dominant limitation in adult kidneys as well. AAV vectors may be intrinsically suboptimal for long term correction of Dent disease type 1.
[0480] In summary, the findings disclosed herein demonstrate that local immune modulation using rapamycin loaded microspheres can substantially enhance and prolong lentiviral mediated CLCN5 gene therapy effects. In contrast, AAV mediated CLCN5 delivery to neonatal kidneys yields only transient improvement of proteinuria despite persistent transgene expression, and adult AAV delivery fails to confer functional correction altogether. These results highlight the critical importance of vector choice, immune control, developmental timing, and cell type specificity' in designing effective gene therapies for Dent disease type 1 and other renal tubulopathies.
[0481] Enumerated Embodiments
[0482] The following enumerated embodiments are provided, the numbering of which should not be construed as indicating levels of importance.
[0483] Embodiment 1 provides a method for treating Dent disease in a subject in need thereof, the method comprising administering to the subject an effective amount of aAtorney Docket Number: 205286-7011W01(00115)
[0484] therapeutic vector comprising a nucleic acid encoding a CLCN5 protein and an effective amount of an immune modulator, thereby treating the disease.
[0485] Embodiment 2 provides the method of claim 1 , wherein the therapeutic vector is a lentiviral vector.
[0486] Embodiment 3 provides the method of claim 1, wherein the therapeutic vector is an adeno-associated virus (AAV) vector.
[0487] Embodiment 4 provides the method of claim 3, wherein the AAV vector comprises a capsid protein of a serotype selected from the group consisting of AAV1, AAV2. AAV3. AAV3B. AAV4. AAV5, AAV6, AAV7, AAV8, AAV9, AAV 12, AAV-Bl, AAV-DJ, AAV -Retro, AAVrh8, AAVrhlO, AAVrh25, Anc80L65, LK03, AAVrhl8, AAVrh74, AAVrh32.33, AAVrh39, AAVrh43, OligoOOl, PHP-B, PHP.eB, and Spark 100.
[0488] Embodiment 5 provides the method of claim 1, wherein the nucleic acid encoding a CLCN5 protein is operably linked to a promoter that drives the expression of the CLCN5 protein.
[0489] Embodiment 6 provides the method of claim 4, wherein the promoter is a constitutive promoter.
[0490] Embodiment 7 provides the method of claim 5, wherein the promoter is an EF-la promoter.
[0491] Embodiment 8 provides the method of claim 2, wherein the therapeutic vector is a lentiviral vector and comprises the nucleic acid sequence set forth in SEQ ID NO. 1.
[0492] Embodiment 9 provides the method of claim 1, wherein the administration of the therapeutic vector and the immune modulator is delivered locally to the kidney.
[0493] Embodiment 10 provides the method of claim 8, wherein the local kidney administration is delivered by a route selected from the group consisting of retrograde ureteral injection and ureteroscopy.
[0494] Embodiment 11 provides the method of claim 1. wherein the immune modulator is rapamycin.
[0495] Embodiment 12 provides the method of claim 1, wherein the immune modulator is comprised within a lipid nanoparticle (LNP).
[0496] Embodiment 13 provides the method of claim 1. wherein the immune modulator is comprised within polymer nanoparticles.Atorney Docket Number: 205286-7011W01(00115)
[0497] Embodiment 14 provides the method of claim 13, wherein the polymer nanoparticle is ImmTOR™.
[0498] Embodiment 15 provides the method of claim 1, wherein the therapeutic vector and immune modulator are delivered concurrently.
[0499] Embodiment 16 provides a method for treating Dent disease in a neonate or pediatric subject in need thereof, the method comprising administering to the subject an effective amount of a lentiviral therapeutic vector comprising a nucleic acid encoding a CLCN5 protein and an effective amount of an immune modulator, thereby treating the disease.
[0500] Embodiment 17 provides the method of claim 16, wherein the nucleic acid encoding a CLCN5 protein is operably linked to a promoter that drives the expression of the CLCN5 protein.
[0501] Embodiment 18 provides the method of claim 17, wherein the promoter is a constitutive promoter.
[0502] Embodiment 19 provides the method of claim 18, wherein the promoter is an EF-1 a promoter.
[0503] Embodiment 20 provides the method of claim 16, wherein the lentiviral vector comprises the nucleic acid sequence set forth in SEQ ID NO. 1.
[0504] Embodiment 21 provides the method of claim 16, wherein the administration of the lentiviral vector and the immune modulator is delivered locally to the kidney.
[0505] Embodiment 22 provides the method of claim 21, wherein the local kidney administration is delivered by a route selected from the group consisting of retrograde ureteral injection and ureteroscopy.
[0506] Embodiment 23 provides the method of claim 16, wherein the immune modulator is rapamycin.
[0507] Embodiment 24 provides the method of claim 16, wherein the immune modulator is comprised within a lipid nanoparticle (LNP).
[0508] Embodiment 25 provides the method of claim 1 , wherein the immune modulator is comprised within polymer nanoparticles.
[0509] Embodiment 26 provides the method of claim 25, wherein the polymer nanoparticle is ImmTOR™.Atorney Docket Number: 205286-7011W01(00115)
[0510] Embodiment 27 provides the method of claim 16, wherein the therapeutic vector and immune modulator are delivered concurrently.
[0511] Embodiment 28 provides a method for treating Dent disease in an adult subject in need thereof, the method comprising administering to the subject an effective amount of a therapeutic AAV vector comprising a nucleic acid encoding a CLCN5 protein and an effective amount of an immune modulator, thereby treating the disease.
[0512] Embodiment 29 provides the method of claim 28, wherein the nucleic acid encoding a CLCN5 protein is operably linked to a promoter that drives the expression of the CLCN5 protein.
[0513] Embodiment 30 provides the method of claim 29, wherein the promoter is a constitutive promoter.
[0514] Embodiment 31 provides the method of claim 30, wherein the promoter is an EFla promoter.
[0515] Embodiment 32 provides the method of claim 28, wherein the therapeutic vector is a lentiviral vector and comprises the nucleic acid sequence set forth in SEQ ID NO. 1.
[0516] Embodiment 33 provides the method of claim 28, wherein the administration of the therapeutic vector and the immune modulator is delivered locally to the kidney.
[0517] Embodiment 34 provides the method of claim 33, wherein the local kidney administration is delivered by a route selected from the group consisting of retrograde ureteral injection and ureteroscopy.
[0518] Embodiment 35 provides the method of claim 28, wherein the immune modulator is rapamycin.
[0519] Embodiment 36 provides the method of claim 28, wherein the immune modulator is comprised within a lipid nanoparticle (LNP).
[0520] Embodiment 37 provides the method of claim 36, wherein the immune modulator is comprised within polymer nanoparticles.
[0521] Embodiment 38 provides the method of claim 37, wherein the polymer nanoparticle is ImmTOR™
[0522] Embodiment 39 provides the method of claim 28, wherein the therapeutic vector and immune modulator are delivered concurrently.
[0523] Embodiment 40 provides a pharmaceutical composition comprising:
[0524] a. a therapeutic vector comprising a nucleic acid encoding a CLCN5 protein;Atorney Docket Number: 205286-7011W01(00115)
[0525] b. a lipid nanoparticle comprising an immune modulator; and
[0526] c. a pharmacologically acceptable vehicle.
[0527] Embodiment 41 provides the pharmaceutical composition of claim 40, wherein the therapeutic vector is a lentiviral vector.
[0528] Embodiment 42 provides the pharmaceutical composition of claim 40, wherein the lentiviral vector comprises an amino acid sequence of SEQ ID NO: 1.
[0529] Embodiment 43 provides the pharmaceutical composition of claim 40, wherein the therapeutic vector is an AAV vector.
[0530] Embodiment 44 provides the pharmaceutical composition of claim 40, wherein the AAV vector comprises a capsid protein of a serotype selected from the group consisting of AAV 1, AAV2, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV12, AAV-B1, AAV-DJ, AAV-Retro, AAVrh8, AAVrhlO, AAVrh25, Anc80L65. LK03, AAVrhl8, AAVrh74, AAVrh32.33, AAVrh39, AAVrh43, OligoOOl, PHP-B, PHP.eB, and SparklOO.
[0531] Embodiment 45 provides a method for correcting a mutation in the CLCN5 gene in a subject in need thereof, comprising administering to the subject with a therapeutic vector comprising a nucleic acid encoding a CLCN5 protein and a lipid nanoparticle (LNP) comprising an immune modulator.
[0532] Embodiment 46 provides the method of claim 45, wherein the therapeutic vector is a lentiviral vector.
[0533] Embodiment 47 provides the method of claim 45, wherein the therapeutic vector is a AAV vector.
[0534] Embodiment 48 provides the method of claim 45, wherein the AAV vector comprises a capsid protein of a serotype selected from the group consisting of AAV1, AAV2, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV12, AAV-Bl, AAV-DJ, AAV-Retro. AAVrh8, AAVrhlO, AAVrh25, Anc80L65, LK03, AAVrhl8, AAVrh74, AAVrh32.33. AAVrh39. AAVrh43, OligoOOl, PHP-B, PHP.eB, and SparklOO.
[0535] Embodiment 49 provides the method of claim 45, wherein the nucleic acid vector is operably linked to a promoter that drives expression of the CLCN5 protein.
[0536] Embodiment 50 provides the method of claim 49, wherein the promoter is a constitutive promoter.Atorney Docket Number: 205286-7011W01(00115)
[0537] Embodiment 51 provides the method of claim 50, wherein the promoter is an EF-1 a promoter.
[0538] Embodiment 52 provides the method of claim 45, wherein the lentiviral vector is encoded by the nucleic acid sequence set forth in SEQ ID NO: 1.
[0539] Embodiment 53 provides the method of embodiments 1, 16. or 28 wherein the immune modulator is comprised within polymeric microspheres.
[0540] Embodiment 54 provides the method of embodiment 53, wherein the polymeric microspheres are formulated for sustained release of the immune modulator.
[0541] Other Embodiments
[0542] The recitation of a listing of elements in any definition of a variable herein includes definitions of that variable as any single element or combination (or sub combination) of listed elements. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.
[0543] The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety. While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims are intended to be construed to include all such embodiments and equivalent variations.
Claims
Attorney Docket Number: 205286-7011W01(00115)CLAIMSWhat is claimed:
1. A method for treating Dent disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a therapeutic vector comprising a nucleic acid encoding a CLCN5 protein and an effective amount of an immune modulator, thereby treating the disease.
2. The method of claim 1, wherein the therapeutic vector is a lentiviral vector.
3. The method of claim 1 , wherein the therapeutic vector is an adeno-associated virus (AAV) vector.
4. The method of claim 3, wherein the AAV vector comprises a capsid protein of a serotype selected from the group consisting of AAV1, AAV2, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV12, AAV-B1, AAV-DJ, AAV-Retro, AAVrh8, AAVrhlO, AAVrh25, Anc80L65, LK03, AAVrhl8, AAVrh74, AAVrh32.33, AAVrh39, AAVrh43, OligoOOl. PHP-B, PHP.eB, and Spark 100.
5. The method of claim 1, wherein the nucleic acid encoding a CLCN5 protein is operably linked to a promoter that drives the expression of the CLCN5 protein.
6. The method of claim 4, wherein the promoter is a constitutive promoter.
7. The method of claim 5, wherein the promoter is an EF-la promoter.
8. The method of claim 2, wherein the therapeutic vector is a lentiviral vector and comprises the nucleic acid sequence set forth in SEQ ID NO. 1.
9. The method of claim 1 , wherein the administration of the therapeutic vector and the immune modulator is delivered locally to the kidney.Attorney Docket Number: 205286-7011W01(00115)10. The method of claim 8, wherein the local kidney administration is delivered by a route selected from the group consisting of retrograde ureteral inj ection and ureteroscopy.
11. The method of claim 1 , wherein the immune modulator is rapamycin.
12. The method of claim 1. wherein the immune modulator is comprised within a lipid nanoparticle (LNP).
13. The method of claim 1, wherein the immune modulator is comprised within polymer nanoparticles.
14. The method of claim 13, wherein the polymer nanoparticle is ImmTOR™.
15. The method of claim 1, wherein the therapeutic vector and immune modulator are delivered concurrently.
16. A method for treating Dent disease in a neonate or pediatric subject in need thereof, the method comprising administering to the subject an effective amount of a lentiviral therapeutic vector comprising a nucleic acid encoding a CLCN5 protein and an effective amount of an immune modulator, thereby treating the disease.
17. The method of claim 16, wherein the nucleic acid encoding a CLCN5 protein is operably linked to a promoter that drives the expression of the CLCN5 protein.
18. The method of claim 17, wherein the promoter is a constitutive promoter.
19. The method of claim 18, wherein the promoter is an EF- la promoter.Attorney Docket Number: 205286-7011W01(00115)20. The method of claim 16, wherein the lentiviral vector comprises the nucleic acid sequence set forth in SEQ ID NO. 1.
21. The method of claim 16, wherein the administration of the lentiviral vector and the immune modulator is delivered locally to the kidney.
22. The method of claim 21, wherein the local kidney administration is delivered by a route selected from the group consisting of retrograde ureteral inj ection and ureteroscopy.
23. The method of claim 16, wherein the immune modulator is rapamycin.
24. The method of claim 16, wherein the immune modulator is comprised within a lipid nanoparticle (LNP).
25. The method of claim 16, wherein the immune modulator is comprised within polymer nanoparticles.
26. The method of claim 25, wherein the polymer nanoparticle is ImmTOR™27. The method of claim 16, wherein the therapeutic vector and immune modulator are delivered concurrently.
28. A method for treating Dent disease in an adult subject in need thereof, the method comprising administering to the subject an effective amount of a therapeutic AAV vector comprising a nucleic acid encoding a CLCN5 protein and an effective amount of an immune modulator, thereby treating the disease.
29. The method of claim 28, wherein the nucleic acid encoding a CLCN5 protein is operably linked to a promoter that drives the expression of the CLCN5 protein.
30. The method of claim 29, wherein the promoter is a constitutive promoter.Attorney Docket Number: 205286-7011W01(00115)31. The method of claim 30, wherein the promoter is an EF-1 a promoter.
32. The method of claim 28, wherein the therapeutic vector is a lentiviral vector and comprises the nucleic acid sequence set forth in SEQ ID NO. 1.
33. The method of claim 28, wherein the administration of the therapeutic vector and the immune modulator is delivered locally to the kidney.
34. The method of claim 33, wherein the local kidney administration is delivered by a route selected from the group consisting of retrograde ureteral inj ection and ureteroscopy.
35. The method of claim 28, wherein the immune modulator is rapamycin.
36. The method of claim 28, wherein the immune modulator is comprised within a lipid nanoparticle (LNP).
37. The method of claim 28, wherein the immune modulator is comprised within polymer nanoparticles.
38. The method of claim 37, wherein the polymer nanoparticle is ImmTOR™.
39. The method of claim 28, wherein the therapeutic vector and immune modulator are delivered concurrently.
40. A pharmaceutical composition comprising:a. a therapeutic vector comprising a nucleic acid encoding a CLCN5 protein; b. a lipid nanoparticle comprising an immune modulator; andc. a pharmacologically acceptable vehicle.Attorney Docket Number: 205286-7011W01(00115)41. The pharmaceutical composition of claim 40, wherein the therapeutic vector is a lentiviral vector.
42. The pharmaceutical composition of claim 40, wherein the lentiviral vector comprises an amino acid sequence of SEQ ID NO: 1.
43. The pharmaceutical composition of claim 40, wherein the therapeutic vector is an AAV vector.
44. The pharmaceutical composition of claim 40, wherein the AAV vector comprises a capsid protein of a serotype selected from the group consisting of AAV1, AAV2, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV12, AAV-B1. AAV-DJ, AAV-Retro, AAVrh8, AAVrhlO, AAVrh25, Anc80L65. LK03, AAVrhl8, AAVrh74. AAVrh32.33, AAVrh39, AAVrh43. OligoOOl, PHP- B, PHP.eB, and SparklOO.
45. A method for correcting a mutation in the CLCN5 gene in a subject in need thereof, comprising administering to the subject with a therapeutic vector comprising a nucleic acid encoding a CLCN5 protein and a lipid nanoparticle (LNP) comprising an immune modulator.
46. The method of claim 45, wherein the therapeutic vector is a lentiviral vector.
47. The method of claim 45, wherein the therapeutic vector is a AAV vector.
48. The method of claim 45, wherein the AAV vector comprises a capsid protein of a serotype selected from the group consisting of AAV1. AAV2. AAV3, AAV3B. AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV12, AAV-B1, AAV-DJ, AAV-Retro, AAVrh8, AAVrhlO, AAVrh25, Anc80L65, LK03, AAVrhl8, AAVrh74, AAVrh32.33, AAVrh39, AAVrh43, OligoOOl, PHP-B, PHP.eB, and SparklOO.Attorney Docket Number: 205286-7011W01(00115)49. The method of claim 45, wherein the nucleic acid vector is operably linked to a promoter that drives expression of the CLCN5 protein.
50. The method of claim 49, wherein the promoter is a constitutive promoter.
51. The method of claim 50, wherein the promoter is an EF-1 a promoter.
52. The method of claim 45, wherein the lentiviral vector is encoded by the nucleic acid sequence set forth in SEQ ID NO: 1.
53. The method of claim 1, 16, or 28 wherein the immune modulator is comprised within polymeric microspheres.
54. The method of claim 53, wherein the polymeric microspheres are formulated for sustained release of the immune modulator.
